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ABSTRACT 
 
Matrix metalloproteinases (MMP) and especially MMP-8 is one of the most widely 
reported oral fluid biomarkers and a promising target candidate for periodontal point-
of-care (POC) diagnostics. Periodontitis is associated with increased oral fluid MMP-8 
levels, which typically decrease after conventional periodontal treatments. Employing 
the measurement of oral fluid MMP-8 levels diagnostically, however, is complicated due 
to high variability.  Chronic periodontal inflammation can induce MMP-8 expression in a 
wide array of cell types, although a great extent of the MMP-8 detected from the gingival 
crevicular fluid (GCF) originates from polynuclear neutrophil granulocytes (neutrophils). 
MMP-8 mediates periodontal tissue breakdown by processing extracellular matrix (ECM) 
proteins with a wide substrate specificity. There is also increasing evidence that MMP-8 
contributes to inflammatory signaling cascades and has a protective role in periodontitis 
and cancer. Thus, it is important to define and differentiate a (statistical) range of 
physiological fluctuations in the oral fluid MMP-8 POC diagnostics, from the 
pathologically high MMP-8 levels. 
The aim of this study was to study methodological and biological reasons for the 
large variability of GCF MMP-8 and further to evaluate the utility of GCF MMP-8 for POC 
diagnostics and its ability to predict the treatment outcome after the conventional scaling 
and root plaining (SRP) treatment and during the supportive maintenance period.  
Different laboratory and POC MMP-8 detecting methods were compared to study 
methodological reasons of variability in the GCF MMP-8 levels. In addition, correlations 
between different inflammatory GCF biomarkers and MMP-8 were compared.  
The MMP-8 levels measured with laboratory methods or POC tests/devices based 
on the same monoclonal antibody were clearly in agreement and correlated significantly. 
There was surprisingly large variability in MMP-8 levels, however, when measured with 
different assays based on different antibodies.    
The comparison of different GCF biomarkers revealed highly discriminating 
properties, especially for myeloperoxidase (MPO) and MMP-8, to differentiate both 
healthy and gingivitis sites from moderate to advanced chronic periodontitis sites.  
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The longitudinal variability in GCF MMP-8 response patterns was explored and the 
prognostic utility of GCF MMP-8 was studied. Distinct response patterns during the 
maintenance period could be found via cluster analysis, especially among smoking 
patients. High MMP-8 levels at baseline and especially the high-responding pattern 
among smokers during the maintenance period predicted the compromised treatment 
outcome.  
The utility of the GCF MMP-8 levels in the prognostic POC diagnostics was further 
studied within a heterogenic population by combining different independent datasets. 
Continuously high MMP-8 levels, at baseline and during the maintenance period, 
predicted an increased risk for compromised treatment outcome for both non- smoking 
and smoking patients. Low MMP-8 levels decreased the risk respectively.  
Overall, the different MMP-8 antibodies can have a quite large difference in 
affinities to different MMP-8 isoforms, causing variability to the measured levels. If 
researchers fail to use the same detection methods in different studies, result 
comparisons may be complicated. GCF MMP-8, however, is a promising candidate as a 
prognostic biomarker to identify sites with an increased risk for compromised treatment 
outcome. This study also strongly supports the evidence that MMP-8 can diagnostically 
differentiate between periodontitis and healthy or gingivitis sites and can also be used 
for the quantitative, therapeutic monitoring of treatment outcome. Different GCF MMP-8 
cutoff levels should be applied for smokers and non-smokers in the MMP-8 based POC 
diagnostics, however. 
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1. REVIEW OF THE LITERATURE 
 
1.1. Classification of periodontal diseases 
 
 Periodontal diseases have been classified as either non-destructive (gingival and 
reversible) or destructive diseases and further etiologically into different sub categories. 
For non-destructive, “gingival”, diseases, the principle subcategories are “plaque–
induced” and “primarily non-plaque-induced” lesions. Plaque-induced diseases are 
further classified by different modifying factors, which define over 40 different gingival 
diseases and conditions in the classification system. (Armitage1999)  
Periodontitis, in general, refers to the bacteria-induced, inflammatory, destructive 
periodontal diseases associated with the breakdown of the tissues surrounding teeth.  
The pathogenesis of periodontitis comprises different etiological risk and modifying 
factors. According to a classification system published in 1999, destructive periodontal 
diseases are classified into seven principal categories. These categories include: i) 
chronic periodontitis, ii) aggressive periodontitis, iii) periodontitis as a manifestation of 
systemic disease, iv) necrotizing periodontal disease, v) abscesses of the periodontium, 
vi) periodontitis associated with endodontic lesions, and vii) developmental or acquired 
deformities and conditions. This thesis study focuses on the first two categories: chronic 
periodontitis and aggressive periodontitis.  Chronic periodontitis is the most common 
form of destructive periodontal disease.  
The 1999 classification system has been criticized for being impractical due to 
complex and multiple main and sub categories. Comparisons between different 
independent studies proves difficult when the extent and severity of periodontitis cases 
lack precise definitions (van der Velden2005). Another major clinical challenge is to 
distinguish between destructive periodontal diseases, especially aggressive and chronic 
periodontitis, because the exact moment of disease onset is often unknown. Aggressive 
periodontitis usually affects younger patients but there is no definitive age relatedness 
in the disease. According to the epidemiological knowledge and the classification system 
based on it, chronic periodontitis cannot rule out aggressive periodontitis in the course 
of disease, i.e. chronic periodontitis can turn into aggressive periodontitis. On the other 
hand, the “chronic” attribute does not imply that it is untreatable (Armitage1999).  Much 
research has been pursued to define inflammatory or microbial biomarkers that could 
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differentiate between chronic and aggressive periodontitis, however no single biomarker 
or composite of markers is yet known to differentiate between the disease types 
(Armitage2013).  
Van der Velden (2005) argued for a nominalistic classification system in contrast to 
an essentialistic system aiming to categorize a disease according etiological factors. In 
the nominalistic system, a certain disease label is given based on well-defined signs and 
symptoms of the disease. The nominalistic classification could be more practical in the 
case of periodontitis with the common signs and symptoms of the diseases but with the 
complex and variable etiological factors. Van der Velden (2005) suggested a nominalistic 
classification system based on four dimensions: extent (number of affected teeth), 
severity (amount of attachment/bone loss per tooth), age (if the moment of disease onset 
is known) and clinical characteristics (necrotizing, rapidly progressive, or refractory 
periodontitis for example). The nominalistic classification would facilitate better 
population comparison between epidemiological studies. The fifth European consensus 
workshop in periodontology has also given a proposal, based on the extent and the 
severity of disease, for the periodontitis case definition to be implied in epidemiological 
studies (Tonetti et al. 2005).     
Smoking- and diabetes-associated periodontal diseases have been discussed 
regarding whether they should be classified as independent entities (Lopez & 
Baelum2012). However, the classification system has not been collectively renewed since 
the 1999.  
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1.2. Etiology of periodontal diseases 
 
Periodontal diseases are considered etiologically complex. An important notion in 
an epidemiological causal theory and model (sufficient-component cause model) for 
complex and multi causal diseases is that a single risk factor cannot cause the disease in 
isolation (Heaton & Dietrich2012). Causal etiological risk factors of destructive 
periodontal diseases, referred to here as periodontitis, can be divided into modifiable and 
non-modifiable factors. Modifiable risk factors include: environmental, acquired, and 
behavioral; whilst non-modifiable risk factors include: age, gender and heredity (genetic 
and epigenetic factors) (Borrell & Papapanou2005).  
Three modifiable factors, including high-level colonization by specific bacteria (A. 
actinomycetemcomitans, P. gingivalis, T. forsythia), smoking, and uncontrolled diabetes, 
are considered to be established risk factors for chronic periodontitis based on consistent 
evidence from multiple independent epidemiological studies (Borrel & Papapanou2005).  
In addition, there are many other putative modifiable factors, such as socio-economic 
factors, HIV, obesity, osteopenia/osteoporosis, vitamin D deficiency, and psychosocial 
factors, supported by a variable amount of evidence (Page & Kornman1997, Borrell & 
Papapanou2005, Stabholz et al. 2010, Genco & Borgnakke2013). The modifying effects of 
smoking in relation to the pathogenesis of periodontal diseases and immunity are 
addressed in more detail in a later chapter.  
There is a specific list of systemic diseases with the manifestation of periodontitis 
classified as an own disease category (Armitage 1999).  The same main category also 
includes the sub category of periodontitis associated with genetic disorders (familial 
neutropenia, Papillon- Lefèvre syndrome, down syndrome etc.), which is not addressed 
here when referred to the genetic susceptibility of periodontitis.   
It is well documented that the prevalence of periodontitis varies in different ethnic 
groups and geographic locations. Especially aggressive periodontitis is more common in 
the African population and in descendants of Africans (1-5%) compared to Caucasians 
(0.1-0.5 %), Asians (0.2-1%), or Hispanics (in North America, 0.5- 1%) (Susin et al. 2014). 
However, the difference in prevalence of periodontitis between different ethnic groups 
is not so consistent if age, behavioral and socio economic factors are taken into account 
(Borrel & Papapanou2005).  There is also much evidence from different populations that 
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periodontitis is more frequent in males compared to females. There is insufficient 
evidence to declare male gender as a risk factor for the onset of disease, but men have a 
higher risk for severe forms of the disease. The difference is explained with behavioral 
aspects. Plausible biological mechanisms, an effect of sex hormones on the immune 
system for example, that may explain the difference, are yet to be described, but cannot 
be ruled out. (Borrell & Papapanou2005, Haytac et al. 2013).  
The evidence gathered from twin and familial aggregation studies suggest that 
genetic factors can explain a major part of variance in population prevalence of both 
chronic and aggressive periodontitis (Michalowicz et al. 1991, Michalowicz et al. 2000, 
Laine et al. 2012). However, there have been arguments that the genetic influence on 
disease severity may have been overestimated in earlier twin studies (Torres de Heens 
et al. 2010).  
A few candidate genes have been found from case-control studies associating single 
nucleotide polymorphisms (SNPs) in genes with chronic (IL-1β, IL-1RN, IL-6, IL-10, 
CD14, vitamin D receptor, MMP-1 and TLR4) or aggressive periodontitis (IL-1β, IL-1RN, 
FcγRIIIb, vitamin D receptor, TLR4) reviewed by Laine et al. (2012). However, an 
increasing number of candidate genes, varying in different populations/studies, are 
being explored in the era of genome-wide association studies (GWAS) (Schaefer et al. 
2010, Divaris et al. 2013, Teumer et al. 2013, Schaefer et al. 2014, Kallio et al. 2014).  
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1.3. Pathogenesis of periodontal diseases 
 
1.3.1. The role of microbiota in periodontal diseases  
Periodontitis, in general, is considered to be a polymicrobially-induced 
inflammatory disease with a destructive host response against the putative periodontal 
pathogens. There is an abundant literature and a long history of studies that associate 
certain bacteria (P.gingivalis, T.denticola, T. forsythia, A.actinomycetemcomitans etc.), and 
an ecological shift (dysbiosis) of biofilm structure, with periodontitis (Haffajee & 
Socransky1994, Socransky et al. 1998, Socransky & Haffajee2005). Nevertheless, the 
development of culture-independent detection methods and high-throughput 
sequencing have revealed a large bacterial diversity and enhanced our understanding of 
the role of bacteria in periodontitis (Kumar et al. 2005, Colombo et al. 2009, Griffen et al. 
2012).  The theory of “red complex” putative periodontal pathogens, according to the 
classical study of Socransky et al. (1998), has evolved to a model of polymicrobial synergy 
and dysbiosis (PSD-model) (Hajishengallis & Lamont2012). The need to update the 
paradigm has arisen from the fact that the putative periodontal pathogens also frequently 
associate with healthy periodontium. The PSD-model does not deny the importance of 
the “red complex” or the other putative pathogens in periodontitis but it focuses on their 
role and better describes the mechanism in disruption of balance between host 
responses and microbes in periodontal diseases (for example, P. gingivalis as a keystone 
pathogen) (Darveau et al. 1998, Hajishengallis et al. 2011, Hajishengallis et al. 2012). It 
has also been discussed whether the association between the putative periodontal 
pathogens and the dysbiosis, an increased proportion of gram- negative anaerobes, and 
periodontitis is a cause or result of inflammation (Bartold & Van Dyke2013, 
Hajishengallis & Lamont2012). The dysbiosis and the success of putative periodontal 
pathogens in periodontitis sites could also be a result of chronic inflammation, which can 
change the environment in the periodontal sulcus to favor the growth of asaccharolytic 
bacterial species. An increased flow of GCF from inflamed periodontal tissue carries 
amino acids and peptides, breakdown products from inflamed tissue, which are nutrients 
especially for many putative periodontal pathogens, the asaccharolytic gram-negative 
anaerobes (Bartold & Van Dyke2013). 
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1.3.2. Host response in the pathogenesis of periodontal diseases 
 Microbes are obligatory in the induction of (plaque induced) periodontal diseases, 
but equal importance should be placed on the alteration of the immunological host 
response against the microbiota in the development and progression of different types 
of periodontitis. There is a continuous interplay between the periodontal microbiota and 
defense mechanisms and immune system around the gingival crevice 
(Hajishengallis2014). According to the epidemiological model, the host-response-related 
component causes can be considered equally important in the initiation and progression 
of periodontitis. The term component cause is synonymous with the terminology of risk 
factor (Heaton & Dietrich2013). Putative periodontal pathogens are considered to be 
necessary, but not solely sufficient, cause to initiate periodontitis.  The host-response-
related component causes can vary from patient to patient and form, together with the 
causal pathogens, classes of sufficient causes, a constellation of periodontal diseases 
associated with partly different component causes, i.e. risk factors.   
 Many of the host-response-related, established (uncontrolled diabetes and 
smoking) and putative components causes (e.g. obesity/metabolic syndrome and vitamin 
D deficiency), can cause or at least are associated with changes/modifications in the 
immune system. Smoking as a risk factor and modifying effect on host response is 
described below in more detail as a major object of this thesis.  Immunity is schematically 
divided into the innate and the adaptive immune systems, irrespective of whether prior 
learning is required to activate the system. A classical histopathological study of the 
different types of periodontal diseases revealed a gradual shift from the innate-
immunity-related cell types in the initial and the early gingivitis lesions to the adaptive-
immunity-associated plasma cells and the general features of chronic inflammation in the 
established gingivitis and the advanced periodontitis lesions (Page & Schroeder1976).  
However, in a longstanding chronic inflammatory condition, both immune systems can 
be considered to work together with diverse feedback mechanisms that impact each 
other (Figure 1).  Different aspects of the immune system, related to the pathogenesis of 
periodontal diseases, which may cause biological variability to MMP-8 levels, are 
reviewed in more detail in the following chapters. 
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1.3.3. Innate immunity and neutrophil responses in periodontal diseases 
 The innate immune system operates as an inherent defense mechanism that does 
not require prior learning. It is permanently active, even in healthy periodontal sites, 
evident from a continuous flow of neutrophils through the junctional epithelium (Page & 
Schroeder1976, Scott & Krauss2012).   
 Innate-immune-system triggered inflammation is activated after periodontal 
pathogens have invaded through the first line of defense in the periodontium; comprising 
intact junctional epithelium and a constant flow of GCF and antibacterial products. Pro-
inflammatory cytokines (IL-1?, IL-6, TNF-α) link the innate and the adaptive immune 
systems together by recruiting and activating the adaptive immune system related cells 
(Preshaw & Taylor2011, Ebersole2003, Kinane et al. 2011).  (Figure1)  
 Innate defense systems became established during a long evolutionary relationship 
between multicellular species and bacteria. This has resulted in an inherent capability of 
the innate immune system to recognize distinct microbial structures, so called pathogen 
associated molecular patterns (PAMPs) (Hajishengallis2014, Di Benedetto et al. 2013, 
Kinane et al. 2007, Preshaw & Taylor2011). These patterns are identified by the pattern 
recognizing receptors (PRR),  such as the toll-like receptors (TLR) that are expressed in 
diverse cell types (neutrophils, monocyte lineage cell, specialized T cells, dendritic cells, 
epithelial cells)(Kinane et al. 2007). TLR and other PRR are important in host-microbe 
interactions to regulate inflammatory responses appropriate for commensal vs. 
pathogenic periodontal microbes (Kinane 2007). Recognition of virulent pathogens leads 
to: pro-inflammatory chemokine and cytokine production in sentinel cells (macrophages, 
dendritic cells, epithelial cells etc.); complement activation and recruitment; the 
emigration of circulating neutrophils; and further stimulation of the adaptive immune 
responses (Di Benedetto et al. 2013, Kinane et al. 2007, Hajishengallis2014, Krauss et al. 
2010).  
 Neutrophils are considered to be key players in the protection of the periodontium 
against the microbiota. Neutrophils form a barrier around the sulcular epithelium, and 
their balanced functions are important in the maintainance of health in periodontal 
tissues. Even healthy periodontium has a small but constant flow of neutrophils through 
the epithelium into the gingival crevice (Page & Schroeder1976) (Figure 1). Adverse 
neutrophil counts and function-related disorders have been associated with 
periodontitis. Decreased counts of circulating neutrophils (neutropenia), impaired 
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functions with normal neutrophil counts, and hyper-reactive or constitutively 
hyperactive neutrophils are all associated with periodontitis (Scott & Krauss2012, 
Nussbaum & Shapira2011). 
 During the maturation period in bone marrow, neutrophils synthesize different 
proteolytic enzymzes (i.e. elastase, MMP-8, MMP-9), antimicrobial proteins (i.e. 
azurosidin, lactoferrin) and reactive oxygen species generating MPO and store them in 
the different granules (Borregaard et al. 2007). The coordinated release of the granule 
content causes ECM breakdown, enables neutrophil migration (MMP-8, MMP-9, 
elastase), and facilitates extracellular antimicrobial actions. Nevertheless, the neutrophil-
derived factors also have many inflammation-regulating effects (Borregaard2010, Van 
Lint & Libert2006, Hajishengallis2014). The infiltrating neutrophils release many pro-
inflammatory cytokines, (IL-8, alarmins), and the ECM-degrading proteases can 
modulate chemokine functions (Borregaard2010, Nauseef & Borregaard2014). The 
neutrophil-originated proteinases, MMP-8 and MMP-9 for example, can cleave LPS-
induced CXC chemokines (LIX), CXC motif chemokine -5 [CXCL5, called also epithelial-
derived neutrophil-activating peptide 78 (ENA-78)] and -6 (CXCL6), to more potent N-
terminally truncated form (Van Lint & Libert2006, Van Den Steen et al. 2003). In addition, 
neutrophils secrete the alarmins (i.e. β-defensin, azurocidin), an endogenous equivalent 
to PAMP, which recruit monocytes and other antigen presenting cells (APC) (Soehnlein 
& Lindbom2009). Azurocidin is a unique antimicrobial neutrophil-derived protein. It 
belongs evolutionarily to the serine proteinase super family but has lost its proteolytic 
capability through mutation. Azurocidin is stored in both the primary granules and the 
secretory vesicles, which might indicate different functions. In recent studies, azurocidin 
has also been proven to have signaling, alarmin-like functions in addition to the long-
known microbicidal effects (Soehnlein & Lindbom2009). 
 Neutrophils kill bacteria through either by phagocytic action and producing 
reactive oxygen species inside the phagosomes, or by extracellular degranulation and 
secretion of microbicidal products. Neutrophil extracellular trap (NET) is a more recently 
found antimicrobial function by neutrophils (Brinkmann et al. 2004). NETs are 
comprised of the extracellular strands of DNA bound with neutrophil-derived proteins. 
NETs are suggested to be produced by a phenomenon called NETosis, which is regarded 
as an alternative cell death besides apoptosis and necrosis (Nauseef & Borregaard2014).  
The microbicidal effects of NETs are controversial but are considered to at least restrain 
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viable bacteria and limit free diffusion of granule-released proteases and tissue damage 
(Nussbaum & Shapira2011). Elastase, MPO, and ROS are essential for NET formation 
(Nauseef & Borregaard2014). Neutrophils of patients with Papillon-Lefévre syndrome, a 
rare genetic disorder, cannot support the NETosis because the lack of elastase and other 
serine proteases. However, number of studies related to NET production in periodontitis 
is low and the role of NET production remains unclear in relation to chronic periodontitis. 
 
1.3.4. Adaptive immunity in the pathogenesis of periodontal diseases 
 Periodontitis is histologically described by characteristic plasma-cell infiltration 
(Page & Schroeder1976, Berglundh & Donati2005). An activation and proliferation of B 
lymphocytes to plasma cells is a part of the adaptive immunological responses. Adaptive 
immunity is stimulated by pro-inflammatory cytokines (IL-1?, IL-6, TNF-α, for example) 
recruiting circulating lympho- and monocytes followed by antigen processing and 
presentation by antigen presenting cells (APCs) (Preshaw & Taylor2011, Kinane et al. 
2011). Dendritic cells and macrophages have traditionally been described as APCs but B 
cells also have antigen presenting functions (Berglundh & Donati2005). Dendritic cells 
are key players between the innate and adaptive immune systems.  They digest, process 
and sample antigens from peripheral tissues and migrate to secondary lymph organs 
mainly lymph nodes to present antigen samples on the major histocompatibility complex 
(MHC) II molecules for naïve B and T cells (Ebersole et al. 2013a).  
 Antigen presentation to naïve CD4+ cells activates T helper (Th) cell differentiation 
to Th1, Th2, or Th17 effector-cell types or regulatory T cells with distinct cytokine 
profiles. The cytokine networks related to Th-cell differentiation are summarized in 
Figure 1.  
 Much research has focused on the roles of cell-mediated (Th1) and humoral (Th2) 
immunity in periodontitis. Histopathological studies indicated that periodontitis lesions 
trigger a predominantly Th2 response with plasma-cell-rich infiltration. It has been 
proposed that Th2 response predispose the host to disease progression as it is inefficient 
to maintain the innate immunity against periodontal microbiota. It also promote IL-1β 
facilitated, osteoclast-mediated, bone resorption. However, an opposite hypothesis has 
also been proposed. (Page & Schroeder 1976, Gaffen & Hajishengallis 2008, Gemmell et 
al. 2002) 
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 The Th1 vs. Th2 paradigm of periodontitis has been refined by the roles of Th17 
and developmentally close induced regulatory T cells (iTreg) (Hajishengallis2014, Gaffen 
& Hajishengallis2008). Th17 acts near the epithelial lining to promote epithelial cells to 
produce antimicrobial products and strengthen neutrophil responses and innate 
immunity against extracellular microbes (Hajishengallis2014). Th17 acts through IL-17, 
which indirectly (through CXC chemokines) induce neutrophil production in the bone 
marrow and chemotactic recruitment into the periodontal tissues (Hajishengallis2014). 
There is also a positive feedback loop between neutrophil-secreted chemokines (CC 
ligand -2 and -20) and the differentiation and the recruitment of Th17 cells into the 
periodontal tissues (Hajishengallis2014, Preshaw & Taylor2011).  Regulatory T cells, in 
contrast, prevent excessive inflammatory responses by expressing anti-inflammatory 
cytokines, transforming growth factor (TGF-) β, and IL-10, which suppress Th1, Th2, and 
Th17 function. The role of Th17 response, beside the Th1 and Th2 responses, must be 
investigated further to understand the role of Th17 in the broad manifestations of 
periodontal diseases (Preshaw & Taylor2011, Gaffen & Hajishengallis2008).  
 
1.3.5. The link between inflammation and bone resorption 
 The breakdown of soft tissue structures in periodontitis is considered to be caused 
by MMPs and other proteases secreted by inflammatory cells: neutrophils, macrophages, 
T cells, B cells, and plasma cells. Chronic inflammatory conditions also induce fibroblast 
and epithelial cells to express MMPs (Sorsa et al. 2006, Hanemaaijer et al. 1997). An 
absolute requirement for bone loss in periodontitis is osteoclast activity and the 
differentiation of osteoclast precursors to active osteoclasts by the stimulation of 
receptor activator of NF-?? (RANK) on the cell surface of osteoclast precursors with 
RANK ligand (RANKL). An inhibiting counterpart for RANKL is osteoprotegerin (OPG), 
which can block RANK activation. (Belibasakis & Bostanci2012)  
 Many cells, such as fibroblasts and osteoblasts, are capable of expressing RANKL, 
but B and T cells are a major source of soluble RANKL (Belibasakis & Bostanci2012). 
Some studies have demonstrated that neutrophils can express cell-membrane RANKL 
under some circumstances but, to facilitate the bone loss in vivo, neutrophils should 
migrate to a close proximity with the bone (Chakravarti et al. 2009).  
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1.3.6. The modifying effect of smoking on the host response 
 Smoking is a major risk factor for periodontitis and has diverse systemic effects, 
which can modify the host response in periodontal diseases (Palmer et al. 2005). Short-
term vasoconstrictive effects on skin capillaries are detected in response to nicotine after 
smoking, although no similar effect has been shown in gingival blood flow or results have 
been contradictory (Palmer et al. 2005). However, there is probably also a long-term 
vasoconstrictive effect on gingival blood flow. Morozumi et al. (2004) showed that after 
a successful smoking cessation, periodontal blood-flow levels increased significantly 
during the following weeks. Gingival blood flow was measured in these studies with a 
laser Doppler device, which can be used to detect only relative changes in blood flow but 
not to compare absolute levels of blood flow between patients. Nevertheless, the relative 
blood flow changes and the GCF volume changes correlated clearly during the follow-up, 
and the GCF volumes were comparable between the nonsmokers and the smokers two 
weeks after quitting smoking (Morozumi et al. 2004). In histological samples, non-
smoking periodontitis patients have had a larger number of blood vessels compared to 
smoking patients (Rezavandi et al. 2002, Palmer et al. 2005). Lower levels of intercellular 
adhesion molecules (ICAM) -1 and E-selectin positive vessels have also been detected in 
smokers compared to non-smokers, which might have had an effect on neutrophil 
transmigration (Rezavandi et al. 2002, Palmer et al. 2005). 
 The effect of smoking on gingival inflammation and bleeding on probing has been 
shown in many large epidemiological studies (Borrell et al. 2005, Eke et al. 2012).  For 
instance, in an experimental intervention study, in which a pro-inflammatory effect of 
plaque accumulation was observed, smokers developed a clinically detectable reduced 
inflammatory response compared to the non-smokers (Bergström & Preber1986). 
 Smoking triggers a wide range of effects on neutrophils, including increased 
circulating neutrophil counts (Palmer et al. 2005). On the other hand, levels of the 
neutrophil-derived proteases (elastase, MMP-8) and other products are reduced in GCF, 
indicating a reduced neutrophil transmigration to the gingival crevice or an impaired 
function (Mäntylä et al. 2006, Ding et al. 1994, Heikkinen et al. 2010, Ozcaka et al. 2011).  
 Peripheral neutrophils from smoking subjects have been shown to release an 
increased amount of free radicals after priming with TNF-α compared to non-smokers 
(Gustafsson et al. 2000). Smoking alone had no significant effect on released radicals after 
the stimulation, but periodontitis itself seemed to own a priming effect on neutrophils 
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(Fredriksson et al. 1999). In more recent studies, cigarette-smoke-extract reduced 
neutrophils’ ability to generate reactive oxidative species (ROS) after the stimulation but 
at high concentration the extracts caused an increased extracellular release of ROS, and 
authors concluded a dual effect of smoking on periodontitis: the impaired elimination of 
bacteria with smaller concentrations of ROS and, in heavy smokers, the oxidative stress 
caused by the increased ROS release (Matthews et al. 2011, Matthews et al. 2012).  
 Tobacco smoking can also have a modulatory effect on immune reactions. 
Decreased counts of infiltrated dendritic cells have been measured among smokers. 
Nicotine affected dendritic cells and the differentiation of CD4+ T cells to Th1, Th2, or 
Th17 cells when stimulated with LPS (Yanagita et al. 2012). Naïve CD4+ T cells were more 
probably differentiated to Th2 cells when exposed to nicotine, as without nicotine, Th1 
cells were the more probable outcome (Yanagita et al. 2012, De Heens et al. 2009). These 
results fit well with the histopathological picture of the dominant plasma-cell presence 
in periodontitis infiltrate (Page & Schroeder1976). 
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1.4. Matrix metalloproteinases 
 
1.4.1. Classification and general aspects of MMPs  
 The proteolytic actions of MMPs were first described by Gross & Lapiere (1962), 
who identified the collagenolytic activity in the metamorphosis of amphibian tadpoles 
(Gross & Lapiere1962). Today, the MMP family is known to comprise 25 structurally 
similar but partly genetically distinct proteolytic, zinc-dependent endopeptidases 
reviewed by Sorsa et al. (2006), Visse & Nagase (2003), and Nagase et al. (2006). Most 
MMPs are extracellular proteinases secreted in an inactive pro-form but membrane 
bound MMPs also exist and certain MMPs can also be activated intracellularly. The 
structure of MMP is composed of similar basic components: the propeptide, the catalytic 
metalloproteinase domain, and the hemopexin domain. There are some exceptions, 
however, and divergence exists in the structure and function of different MMPs (Sorsa et 
al. 2006, Visse & Nagase2003, Nagase et al. 2006).  
 MMPs are classified according to their substrate specificity and structure into six 
groups:  collagenases (MMP-1, -8, -13); gelatinases (MMP-2, -9); stromelysins (MMP-3, 
MMP-10, -11); matrilysins (MMP-7,  -26); membrane-type MMPs (MMP-14, -15,-16, -17, -
25); and other MMPs:  macrophage elastase (MMP-12), MMP-19,  enamelysin (MMP-20). 
Genes coding human collagenases, including MMP-8, are located near to each other on 
chromosome 11 (11q22-q23). (Sorsa et al. 2006, Nagase et al. 2006, Visse & 
Nagase2003).  
 The activity of MMPs is controlled through multiple levels of regulation from gene 
expression to compartmentalization, pro-enzyme activation, and the inhibition of 
activated MMPs. The catalytic domain of MMPs with Zn-ion is blocked with the bond 
between the ion and the cysteine switch in the pro-peptide of latent MMP. The in vivo 
activation of latent MMPs occurs when the bond between the cysteine switch and Zn–ion 
is interrupted by ether a proteolytic cleavage of the pro-peptide or by chemical 
modifications or reactions with oxygen species formed abundantly during inflammation. 
(Sorsa et al. 2006, Nagase et al. 2006, Visse & Nagase2003)  
 Activated MMPs are further regulated through inactivation by the non-specific 
inhibitors (alpha-2-macromolecules) and specific tissue inhibitors (TIMPs) (Sternlicht & 
Werb2001).  Alpha-2-macroglobulins are large glycoproteins, which inhibit MMPs by 
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binding their own proteinase component (Werb et al. 1974).  Alpha-2–macroglobulins 
are the main inhibitors of MMPs in liquid phase, plasma for example (Visse & 
Nagase2003). TIMPs, in contrast, are smaller, more specific inhibitors that bind to the 
catalytic domain of MMPs (Visse & Nagase2003, Sternlicht & Werb2001). Altogether four 
different TIMPs are known and each of them has their specific target MMPs. In addition, 
TIMPs have been shown to have other biological activities (Visse & Nagase2003). TIMP-
1 is the most important inhibitor of active MMP-8 in periodontal tissues (Sorsa et al. 
2006).   
 
1.4.2.  Matrix metalloproteinase-8 isoforms 
 MMP-8 has been isolated (Sorsa et al. 1985, Sorsa1987) and sequenced (Hasty et al. 
1990, Knäuper et al. 1990a), at first from neutrophils, and historically was called 
neutrophil collagenase. However, several cell types from different tissues have been 
proved to express MMP-8. MMP-8 protein and gene expression in vivo has been shown to 
occur in synovial and gingival fibroblasts (Hanemaaijer et al. 1997), cartilage 
chondrocytes (Chubinskaya et al. 1999), epithelial cells (Tervahartiala et al. 2000, Pirilä 
et al. 2001, Prikk et al. 2001), monocytes/macrophages (Prikk et al. 2001), and plasma 
cells (Wahlgren et al. 2001, Kiili et al. 2002). In vitro, even more MMP-8 expressing cell 
types have been found (Sorsa et al. 2006).    
 There are several MMP-8 isoforms with different molecular weights: The latent and 
the active glycosylated neutrophil MMP-8 with the molecular weight (Mr) of 70-75 kDa 
and 50-60 kDa. The non-glycosylated, de novo secreted, “mesenchymal” forms have the 
molecular weight of around 50-40 kDa, whilst lower molecular weight fragments also 
exist (Hanemaaijer et al. 1997, Kiili et al. 2002).  
 Owen et al. (2004) showed that only 15-20% of cellular MMP-8 was freely released 
in soluble form after a pro-inflammatory “physiological” stimulation (TNF-α or PAF+ 
fMLP) and after the stimulation a marked amount of MMP-8 was bound to the outer 
surface of extracellular membrane facilitating neutrophil migration, for example. 
However, MMP-8 lacks the membrane binding domain, which is specific to the 
membrane-type (MT) MMPs and the attachment of “membrane bound” MMP-8 had to be 
achieved with another mechanism. (Owen et al. 2004) 
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 Owen et al. (2004) also further studied differences in MMP-8 isoforms between the 
cell compartments. Freely released, extracellular, soluble MMP-8 was inevitably in the 
latent form with a molecular weight of 85kDa. Inside the specific granules, MMP-8 was 
also detected in the 110, 40, and 30 kDa isoforms, in addition to the major 85kDa form. 
Plasma membranes contained, in turn, MMP-8 in the latent 85 kDa, the active 65 kDa, and 
the fragmented 30 kDa isoforms, and also the minor forms of 110 kDa, 80 kDa, and 46 
kDa. (Owen et al. 2004) 
 Differences in the glycosylation of neutrophil-derived MMP-8 may explain the 
differences in molecular weights between studies. Hanemaaijer et al. (1997) showed the 
difference in the molecular weights of MMP-8 from purified neutrophils extracts or the 
rheumatoid synovial fibroblasts (RSF) and the human umbilical vein endothelial cells 
(HUVEC) culture media in the western blot before and after the deglycosylation. Before 
the deglycosylation, the neutrophil extracts contained MMP-8 isoforms comparative to 
the molecular weights of around 75 kDa, also referred above.  After the deglycosylation, 
the neutrophil extracts contained four bands on the western blot of about 70, 65, 50, and 
45 kDa in weight and also the minor fragmented forms around 30 kDa. RSF and HUVEC 
culture media only had the 50 kDa form on the western blot and deglycosylation had no 
significant effect on the molecular weight of MMP-8.  Glycosylation is most probably 
important for the compartmentalization of MMP-8 into specific neutrophil granules. 
(Hanemaaijer et al. 1997) 
 
1.4.3. Regulation of MMP-8 expression and release 
 IL-1? has been shown to induce MMP-8 expression in gingival fibroblasts (Abe et al. 
2001), and TNF-α in endothelial cells (Hanemaaijer et al. 1997), in vitro.  IL-6 has been 
shown to increase MMP-8 expression in myeloma cells (Wahlgren et al. 2001) and TGF?-
1 has been shown to decrease MMP-8 expression in odontoblasts in vitro (Palosaari et al. 
2000). TGF?-1 levels have also been more increased in MMP-8 knock- out mice with a 
wound healing model suggesting feedback mechanisms between TGF?-1 and MMP-8, 
interestingly (Åström et al. 2014, Balbin et al. 2003). In addition, hyperoxia has been 
shown to promote up-regulation of MMP-8 expression (Cederqvist et al. 2006). 
 In neutrophils, MMP-8 gene expression occurs during the maturation period in the 
bone marrow and the latent protein is stored inside the specific granules (secondary 
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granules) (Bainton et al. 1971, Borregaard et al. 2007).  Neutrophil-originated MMP-8 is 
highly glycosylated, which is assumed to relate to the compartmentalization of MMP-8 
during the neutrophil maturation period (Knäuper et al. 1990b, Hanemaaijer et al. 1997). 
The degranulation of neutrophils and the amount of MMP-8 released to an extracellular 
space is affected by the priming of different cytokines (IL-1?, TNF-α) and the stimulus of 
bacteria derived products (LPS) or other chemical stimulus (oxidative species) (Sorsa et 
al. 2006).  
 
1.4.4. Activators of latent MMP-8 
 The activation of latent MMPs can occur with the proteolytic cleavage as described 
above. The following MMPs or other proteolytic host enzymes can activate the latent 
MMP-8 by the proteolytic modification of pro-domain: MMP-10 (stromelysin-2) 
(Knäuper et al. 1993, Knäuper et al. 1996), MMP-3 (stromelysin 1) (Knäuper et al. 1993), 
MMP-14 (Holopainen et al. 2003), MMP-7 (Dozier et al. 2006), serine protease catepsin 
G (Kähäri & Saarialho-Kere1999, Tervahartiala et al. 1996) and trypsin -2 (Moilanen et 
al. 2003).  
 In addition to proteolytic cleavage, MMP-8 can also be activated by reactive oxygen 
species (Sorsa et al. 1989, Suomalainen et al. 1991, Saari et al. 1990, Saari et al. 1992, 
Weiss et al. 1985). The susceptibility of the neutrophil MMP-8 to ROS is believed to be 
due to the high degree of glycosylation in the neutrophil isoforms (Sorsa et al. 2006).  
MPO, which catalyzes the production of hypochlorous acid (HOCl) from hydrogen 
peroxide (H2O2) and chloride anion (Cl-), is released from the stimulated neutrophils. 
Hypocholorous acid is a potent MMP-8 activator and the coordinated degranulation of 
MPO and the other neutrophil proteases is believed to promote the activation of the latent 
extracellular MMP-8 (Saari et al. 1992, Springman et al. 1990, Sorsa et al. 2006). 
 In addition to host-derived activating factors, the proteolytic cleavage and the ROS 
activation of MMP-8, bacterial species have been noted to promote collagenase activity; 
especially T. denticola and P. gingivalis derived proteases, extracted from the periodontal 
sulcular plaque (Sorsa et al. 1992, Sorsa et al. 1995, Ding et al. 1996, Ding et al. 1997).  
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1.4.5. Biological functions of MMP-8 
 MMP-8 has a wide substrate specificity overlapping with other collagenases. MMP-8 
cleaves collagen types-I, -II –III, -VII, and –X, with the order of specificity to collagen 
I>III>II (Hasty et al. 1987), and a wide array of other ECM substances (Sorsa et al. 2006, 
Van Lint & Libert2006). ECM contains a large amount of latent chemokines and bioactive 
proteins, which are released and activated after proteolytic actions of proteases, 
including MMPs in inflamed periodontal tissue, and leads to complex pro- and anti-
inflammatory cascades of gene expression and inflammatory cell migration. (Van Lint & 
Libert2006). 
 MMP-8 has been revealed to contribute to anti-inflammatory defensive effects in 
experimental models of skin cancer, inflammatory lung diseases, and also in periodontitis 
(Balbin et al. 2003, Owen et al. 2004, Gueders et al. 2005, Kuula et al. 2009). MMP-8 
knockout (KO) mice with P. gingivalis-induced periodontitis demonstrated more alveolar 
bone loss compared to wild-type controls, indicating that MMP-8 has a protective 
physiological role in inflamed tissues (Kuula et al. 2009). Excessively expressed levels 
associate with the active and the unstable disease (Lee et al. 1995, Mäntylä et al. 2003, 
Mäntylä et al. 2006, Sorsa et al. 2015). The anti-inflammatory effects of MMP-8 probably 
result from the processing of chemokines released from degraded ECM. In the wound-
healing model, MMP-8 KO mice exhibited a more diffuse neutrophil migration in the 
tissues compared to the wild type controls (Gutierrez-Fernandez et al. 2007). In addition, 
the KO mice were not able to clear out the infiltrated neutrophils causing a prolonged 
inflammatory response (Gutiérrez-Fernández et al. 2007). Thus, MMP-8 can have an 
effect on the neutrophil recruitment during the up-regulation of inflammation, but also 
the resolution of inflammation in the later periods (Van Lint & Libert 2006).  The ability 
of MMP-8 and MMP-9 to cleave LPS induced CXC chemokine (LIX) to a more potent 
neutrophil attractant is proposed as one possible explanation for the different 
inflammatory-response patterns in the MMP-8 KO and the wild type mice (Balbin et al. 
2003, Van Den Steen et al. 2003, Van Lint & Libert2006, Hernandez et al. 2011). However, 
no direct human in vivo relationship between MMP-8 and LIX have yet been shown (Van 
Lint & Libert 2006). 
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1.4.6. MMP-8 in periodontal diseases 
 Most of the MMP-8 in gingival tissues and GCF is most likely derived from 
neutrophils, although many other cells can express and secret MMP-8 after chronic pro-
inflammatory stimulus as described above. Studies including gingival samples with 
immunohistochemical staining of MMP-8, and expressing strong correlations with pure 
neutrophil-associated GCF biomarkers (elastase, azurocidin, MPO) give support for this 
view (Sternlicht & Werb2001, Uitto et al. 2003, Beklen et al. 2007, Hernandez et al. 2010) 
A major function of the neutrophil-driven neutral proteases, including MMP-8, is to 
enhance neutrophil migration in (periodontal) tissues toward an infection focus-driven 
by the chemo-attracting signal gradients. In MMP-8 knockout mice with P. gingivalis-
induced periodontitis, neutrophils are distributed diffusely when compared to the wild 
types, which may indicate less efficient actions against the microbes (Kuula et al. 2009). 
The degradation of connective tissue enables the inflammatory signaling molecules, 
chemo- and cytokines etc., to spread out more efficiently (Uitto et al. 2003). Thus, the 
effect of MMP-8 in periodontal diseases can be described as a double-edged sword. 
Certain physiological levels of MMP-8 are necessary for efficient neutrophil functions and 
the regulation of inflammatory response in periodontitis, while excessive levels cause 
more tissue breakdown and are associated with a more severe disease and disease 
progression (Lee et al. 1995, Mäntylä et al. 2003, Mäntylä et al. 2006, Kinney et al. 2014, 
Ramseier et al. 2009). 
 
1.4.7. Genetic polymorphisms related to MMP-8 in periodontal diseases  
Three single nucleotide polymorphisms, with possible effects on MMP-8 gene 
expression, have been identified to date in the promoter region of the MMP-8 gene at the 
positions -799 C/T (rs1320632), -381 A/G (rs11225395), and +17 C/G (rs2155052) 
(Ye2000).  The -799 T allele carriers have been associated with aggressive periodontitis 
in the Taiwanese population (Chou et al. 2011) and generalized aggressive periodontitis 
(G-AgP) in the Turkish population when compared to healthy controls (Emingil et al. 
2014). The haplotype -799 T/ +17C has been also associated with CP (Izakovicova Holla 
et al. 2012).  However, these SNPs have not been identified in genome-wide association 
studies of chronic or aggressive periodontitis patients (Schaefer et al. 2010, Divaris et al. 
2013, Teumer et al. 2013, Schaefer et al. 2014, Kallio et al. 2014).  
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In the study of Emingil et al. (2014), polymorphisms in both MMP-8 and TIMP-1 
genes were compared between G-AgP patients and healthy controls in the Turkish 
population and the treatment outcomes between the different genotypes were also 
studied. The conclusion of the study was that the MMP-8 -799 C/T and the TIMP-1 372 
T/C, *429 T/G gene polymorphisms could associate with the susceptibility to G-AgP in 
males.  Small differences in the GCF MMP-8 levels were also reported between the 
genotypes three months after SRP therapy.  
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1.5. Models of the disease progression and the effect of periodontal 
treatments 
 
1.5.1. Natural history of periodontal disease progression - classical studies with 
 untreated patients 
 Patterns of periodontitis disease progression have been studied for decades. 
Classical epidemiological longitudinal follow-up studies have given an impression of a 
linear continuous process of attachment loss, in which the progression rate can vary in 
different populations and by modifying risk factors (Löe et al. 1978). The annual average 
rate of attachment loss in the linear model was approximated to be around 0.1mm with 
the different-aged, randomly-recruited Norwegian males regularly treated by a dentist 
and 0.2 – 0.3 mm in the Sri Lankan population with no dental treatments or preventive 
interventions (Löe et al. 1978). In the cohort studies, like the above described, intervals 
between the follow-ups are usually relatively long, several years, and fluctuations of 
individual or site-specific disease activity between the surveys cannot be detected. 
(Socransky et al. 1984a, Schätzle et al. 2009, Mdala et al. 2014)  
 In another classical longitudinal study by Goodson et al. (1982), untreated 
periodontitis patients were followed once a month during one year. The majority of sites 
(83%) displayed no significant change in the probing measures during the follow-up and 
most of the sites with significant change (increase or decrease of probing measures) 
became shallower, when the patterns of disease progression and regression were 
analyzed (Goodson et al. 1982).  In another study, untreated patients were followed 
bimonthly during one year.  Five percent of sites were observed to lose attachment and 
gain was shown in 2% of sites (Haffajee et al. 1983). Even smaller percentage rates were 
observed if a more conservative statistical method was used to define the significant 
clinical attachment level (CAL) change within the data (Haffajee et al. 1983).  A challenge 
faced in the analysis of longitudinal data is that the detected significant attachment loss 
or the pocket deepening is not permanent during the follow-up (Goodson et al. 1982, 
Haffajee et al. 1983). From the sites with significant pocket depth (PD) increase, 
approximately half retained the deep levels during the follow-up as the rest of sites had 
spontaneous remission (Goodson et al. 1982). Further on, the same authors noticed that 
in a longitudinal study of six years, the annual attachment loss was on average 0.18 mm, 
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comparable with rates in the linear model (Löe et al. 1978), and only 12% expressed the 
attachment loss of more than 2 mm during the period (Socransky et al. 1984). On the 
other hand, 40% of sites that exhibited the attachment loss during the first 3 year period, 
had no change in the next 3 years and 50% of sites with no change in the first 3 years, had 
attachment loss in the last 3 years (Socransky et al. 1984). Comparable results were 
shown in a more recent cohort study of 12 years (with 6 years examination intervals) 
from New Zealand. Only 13.2% of sites were observed to have moderate or markedly 
increasing attachment loss during the 12 years follow-up (Thomson et al. 2013). 
Socransky et al. (1984) proposed, based on the above described discrepancy between the 
estimated annual rates of the linear disease progression and the observations of disease 
progression and regression in relatively short intervals between the examinations, that 
the progression of periodontitis is more a burst-like phenomenon than a continuous 
process.   
 
1.5.2. Transitions between healthy, gingivitis and initial periodontitis states
 – statistical Markovian model 
 The cross sectional mean levels and the changes in respective means of attachment 
loss fail to definitively describe the patient and site specific fluctuations between 
gingivitis and periodontitis lesions during the follow-up. Recently, a more sophisticated 
statistical analysis of transitions between healthy or gingivitis status to periodontitis and 
reverse, i.e. both progression and regression, have been conducted (Schätzle et al. 2009, 
Mdala et al. 2014). Schätzle et al. (2009) used the multistate Markov model to estimate 
probabilities of transitions from healthy to gingivitis and initial periodontitis and reverse 
during the 7 visits of a cohort followed up for 26 years (the same cohort as in Löe et al. 
1978 was followed). Authors concluded that increased mean calculus index and smoking 
were significant predictive covariates for the progression, while increased mean gingival 
index (GI) and younger age predicted the regression of initial periodontitis (Schätzle et 
al. 2009). Authors explained the regressive effect of high GI, a bit paradoxical finding 
compared to earlier results from the same authors (Schätzle et al. 2003), with smoking. 
Smoking probably suppressed inflammatory response and GI, and the smokers were 
more susceptible to the accumulation of plaque and calculus (Schätzle et al. 2009).  
 Mdala et al. (2014) used a similar model to describe transitions of healthy sites to 
gingivitis and periodontitis in a two-year-long clinical trial, which was originally designed 
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to study the effect of different periodontal treatments and adjunctive antimicrobial 
medications on chronic periodontitis patients. Because the follow-up was only 2 years, 
reverse transitions from periodontitis to gingivitis or healthy sites were not allowed in 
the model.  Healthy sites retained their state for an average 32 months; 87-97% of 
transitions were from healthy to gingivitis as a smaller proportion was classified as the 
fast transition from healthy to periodontitis. Smoking and disease severity were 
significant risk factors for the fast transitions (Mdala et al. 2014).  
 
1.5.3. Hierarchy of periodontal data 
 Another major challenge in statistical analyses of periodontal data is the complex 
structure including many levels of hierarchy: site, tooth, and patient level, and repeated 
measures from same sites in longitudinal studies. In this regard, the site level measures 
(including site-specific biomarkers) are not truly independent in statistical analysis. The 
hierarchy can be taken into account with multi-level models or mixed models (Gilthorpe 
et al. 2003, Tu et al. 2004). Gilthorpe et al. (2003) employed such a model to analyze CAL 
changes in 100 patients and 4 sites of all teeth in a longitudinal study of three years, with 
three examination visits. They concluded that the changes in CAL levels were cyclical 
during the follow-up but changes exhibited the dynamic regression to the mean at both 
the tooth and the patient level. This means that both the linear and the burst models of 
disease progression are a manifestation of the same phenomenon depending on the 
perspective and time scale.   
 
1.5.4. Conventional scaling and root plaining treatments 
 The conventional treatment by scaling and root plaining (SRP), and supportive 
maintenance treatment, reduce microbial load, absolute quantity, and relative 
proportion of the putative periodontal pathogens, and should further lead to resolution 
of inflammation.  However, it is a well-known fact that not all sites and patients, although 
a minority, respond well to a given treatment and treatment results cannot be maintained 
after the initial treatments (Drisko2001). Insufficient instrumentation, poor oral hygiene 
compliance and neglect of maintenance visits have been considered major factors for the 
compromised treatment outcome. However, the constitutional and environmental 
factors affecting host response may also be reasons for recurrent periodontitis and the 
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non-responding and the prolonged periodontal inflammation after the treatments 
(Drisko2001). 
 Meta-analysis of SRP treatment has shown PD reduction on average to be around 1 
mm in sites with moderate periodontitis lesion (4-6mm) and 2 mm in advanced lesions 
(>6 mm) as mean CAL gain values has been 0.5 mm and 1 mm, respectively (Hung & 
Douglass2002). The greatest change in PD and CAL values occurs from one to three 
months and the evaluation of treatment outcome is not recommended before one month 
after the treatment. Healing and improvement in clinical parameters can continue even 
several months after the initial treatment (Cobb2002). 
 
1.5.5.  Host response modulating medical treatments  
 There is much evidence promoting the role of host response in the pathogenesis of 
periodontitis and also the host-response-modifying treatment options have been 
developed. The effect of low-dose doxycycline (20 mg twice a day) is based on the 
chelation property of doxycycline toward Ca2+ and Zn2+ dependent proteases (MMPs) 
(Golub et al. 1985, Golub et al. 1990, Ingman et al. 1993, Suomalainen et al. 1992, 
Ashley1999). Doxycycline also suppresses MMP gene expression (Ramamurthy et al. 
1999). In fact, the association of decreased MMP-8 levels with long (several months) LDD 
or antimicrobial tetracycline treatments is probably related to the suppressed gene 
expression more than blocking MMPs; blocking does not necessarily have an effect on the 
affinity of an MMP-8 specific antibody to detect MMP-8 levels (Emingil et al. 2004, Golub 
et al. 2008, Reinhardt et al. 2010, Payne et al. 2011, Kormi et al. 2014).   
 The clinical effect of LDD has been found in multiple studies and the United States 
Food and Drug Administration has approved LDD as an adjunctive medication with SRP 
for periodontal treatment (Caton & Ryan2011). Significant differences have been 
reported in mean PD reduction and CAL gain in patients with SRP adjunctive with LDD 
compared to placebo (Caton & Ryan2011). Clinically, the proportion of sites with 
significant (>2 mm) PD reduction and CAL gain is higher in LDD treated patients 
compared to placebo (Caton & Ryan2011, Preshaw et al. 2005, Preshaw2008).  In some 
studies, non-smokers seemed to benefit more from LDD medication compared to 
smokers (Preshaw et al. 2005, Needleman et al. 2007). 
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1.5.6. Azithromycin as an adjunctive antimicrobial treatment 
 Azithromycin is a wide spectrum antibiotic against aerobic and anaerobic gram-
negative putative periodontal pathogens (Herrera et al. 2008, Muniz et al. 2013). There 
has been an increasing interest in azithromycin usage as an adjunctive medication, 
together with SRP in periodontal diseases because azithromycin has some beneficial 
pharmacological properties (Foulds et al. 1990, Muniz et al. 2013). One 500 mg tablet of 
azithromycin taken once a day for three days is a dosage used to achieve sufficient 
therapeutic levels in tissues for 7 days (Gomi et al. 2007). On the other hand, a long half-
life of azithromycin may be a risk for the development of resistant species, at least shortly 
after taking the medication (Haffajee et al. 2008). Azithromycin has also been shown to 
carry anti-inflammatory properties in addition to its anti-microbial effect (Culic et al. 
2001).  However, somewhat contradictory results have been reported in relation to the 
effect of adjunctive use of azithromycin compared to placebo. Muniz et al. (2013) have 
reviewed clinical double- or single-blinded trials in relation to the adjunctive use of 
azithromycin and they concluded that most studies reported significantly reduced PD 
and increased attachment gain compared to controls. However negative results with no 
significant differences between the placebo and azithromycin have also been reported 
(Dastoor et al. 2007, Han et al. 2012a, Emingil et al. 2012, Sampaio et al. 2011). Some 
studies suggest that azithromycin might have a beneficial effect in the treatment of 
advanced sites with >6 mm deep pockets when the instrumentation is not necessarily 
sufficient to remove all microbial deposits (Emingil et al. 2012). 
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1.6. Oral fluids in periodontal diagnostics 
 
1.6.1. General aspects 
 Oral fluid based diagnostics is drawing increasing scientific interest in periodontal 
research but also in research related to systemic diseases, such as cardiovascular 
diseases or cancer (Sorsa et al. 2004, Sorsa et al. 2006, Sorsa et al. 2011, Sorsa et al. 2015). 
Oral fluids have certain diagnostic advantages, compared to blood samples.  Most 
importantly, oral fluid sampling is non-invasive and a simpler procedure to carry out.  
Oral fluid samples comprise saliva, oral rinse, or gingival crevicular fluid samples. Saliva 
sampling can be further divided to stimulated and non-stimulated saliva samples. All of 
the methods have certain advantages and disadvantages from the perspective of 
periodontal point-of-care diagnostics. Saliva sampling is probably the easiest to perform 
and there is no requirement for dental-professional aid if simple instructions are 
followed. The oral rinse is near to the saliva sampling (Pauletto et al. 2000, Romanelli et 
al. 1999, Mancini et al. 1999). The main difference is that, in the oral rinse sampling, saliva 
is washed out from the oral cavity by rinsing the mouth with water vigorously before the 
actual sampling.  The actual oral rinse sample is collected after the washout by rinsing 
the mouth again with a standard amount of water for a standard time period (Romanelli 
et al. 1999, Mancini et al. 1999). This way, the content of GCF is highlighted in the mouth-
rinse sampling compared to the saliva sample, which is more influenced by the salivary 
gland secretions. GCF is a site-specific sampling method and is less biased by any other 
possible oral pathological conditions (Uitto et al. 2003). Actually, GCF is considered to be 
completely distinct exudate or transudate of gingiva and is not mixed with saliva until 
GCF is flown out of the crevice (Griffiths2003). A disadvantage of GCF sampling is that it 
is technically more demanding compared than saliva or oral-rinse sampling and dental 
professionals are required to perform the sampling to avoid contaminations 
(Griffiths2003).  Also, the amount of obtained GCF in mild gingivitis and healthy sites is 
quite small and a detection of some biomarkers from low levels of GCF can be difficult. 
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 Based on the work developed by Wilson et al. (2007), Kinane et al. (2011) grouped 
biomarkers into five groups according to information the groups give about periodontal 
diseases and if there is any evidence for biomarkers to belong to these groups. 
1) Susceptibility: “A biomarker that prospectively identifies individuals or sites at 
increased risk for periodontal disease”.  
2) Diagnostic:  “A biomarker that identifies the presence of periodontal disease”.  
3) Prognostic: “A biomarker that identifies patients or sites most likely to respond to 
specific interventions”. 
4) Predictive: “A biomarker that predicts future progression of disease.” 
5) Therapeutic: “A biomarker that provides a quantifiable measure of response to 
periodontal therapy” 
 
1.6.2. Gingival crevicular fluid 
GCF is an exudate or transudate filtrated from periodontal tissues into the 
periodontal sulcus (Griffiths2003). The amount of GCF production is affected by capillary 
permeability, lymphatic drainage of interstitial fluid and an osmotic pressure in the 
sulcus formed by bacterial products, host-derived proteins, and other molecules. In 
healthy tissues, capillary permeability is small, most of the interstitial fluid is drained into 
the lymphatic vessels and only a small amount of GCF is transuded into the sulcus. In 
healthy tissues, the osmotic pressure affects the formation of GCF relatively more, 
compared to inflamed tissues where the capillary permeability is increased and the 
lymphatic draining cannot take care of the increased interstitial hydrostatic pressure, 
and the excess of the interstitial exudate is filtrated into the sulcus. There is a difference 
in protein contents between exuded and transuded GCF. The Exuded GCF from inflamed 
periodontium has large co-variation with serum, as the transuded GCF form healthy 
tissues remind more interstitial fluid. (Griffiths2003)  
GCF resting volumes can be ten-fold higher in moderate pockets (0.4 ?l, 4-5 mm) 
and even a 30-fold increase has been observed in deep pockets (1.5 ?l, 6-9 mm) compared 
to healthy sites (0.05 ?l). GCF flow rates have been reported to increase from 3 ?l/h in 
healthy sites to 44 ?l/h in deep pockets. (Goodson2003)    
Significantly lower GCF volumes have been detected among smokers on average, 
but after smoking ceased, GCF volume recovered to levels comparable with non-smokers 
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within two weeks (Morozumi et al. 2004). GCF volume correlated with increasing gingival 
blood flow during the non-smoking period of smokers measured with a laser doppler 
flow meter (Morozumi et al. 2004). 
 
1.6.3. Oral fluid MMP-8 in periodontal diagnostics 
Many studies have sought to detect periodontitis-associated biomarkers from GCF. 
MMP-8 is one of the most studied and reported periodontal biomarkers. A  PubMed 
search with MESH keywords “periodontal disease” and “GCF” produced in total 1090 
articles (published before 2015).  A combination of “MMP-8” (“MMP-8” or “collagenase -
2” or “neutrophil collagenase”) with the before mentioned words produced 90 articles. 
Respective searches for IL-1? was 195, for elastase 86, for TNF-α 74, for MMP-9 36, and 
MMP-13 produced 16 results.   
In addition to the search (“periodontal disease” and “GCF” and MMP-8”), the 
keywords “periodontal disease and MMP-8 (or collagenase or neutrophil collagenase)” 
produced 226 studies. There were a few GCF MMP-8 articles, which could be found with 
the “periodontal disease and MMP-8” search but not with the “periodontal disease and 
GCF and MMP-8” search.   
After a manual check of both searches, 103 MMP-8 and GCF and human 
periodontitis related articles were found and further categorized into four groups of 
studies: i) clinical trials, ii) cross sectional (periodontitis) case-control studies and 
correlation studies of clinical periodontal measures and GCF MMP-8 levels, iii) 
longitudinal studies comparing progressive or active sites vs. stable, and iv)experimental 
studies related to the MMP-8 biological functions (the activation of latent pro-enzyme, 
the direct biological actions, correlations of GCF MMP-8 with other biomarkers, the effect 
of modifying factors on GCF biomarkers etc.)  
Longitudinal studies/clinical trials and cross sectional case-control and correlation 
studies were reviewed in more detail. All included clinical trials (n = 44), the effect of SRP 
was studied alone or in conjunction with host response modifying medication (LDD) or 
some other adjunctive treatment (laser, surgery, NSAID, antibiotics, etc.). The vast 
majority of studies reported decreased average MMP-8 levels, with or without the 
adjunctive treatment.  In 72% of articles, MMP-8 levels were reported to decrease 
significantly after SRP treatment (alone) during variable follow-up periods. In the 
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reviewed studies, with the combination of the SRP and LDD, a significant GCF MMP-8 
reduction was reported in 89% of studies and in 76% of studies if SRP was combined 
with the other medication or treatment (no LDD), respectively. (Table 1)  
The above described search of 103 GCF MMP-8 original articles included 33 cross-
sectional case-control or correlation studies. All the cross sectional studies are presented 
in Table 2. Studies were grouped into three sub-categories according to how clinical 
parameters or disease status were compared with GCF MMP-8: i) A correlation between 
GCF MMP-8 levels and clinical parameters was analyzed, ii) MMP-8 levels between 
healthy and periodontitis sites or patients (pooled GCF) were compared, or iii) GCF MMP-
8 levels between gingivitis and periodontitis sites/patients were compared. Almost all 
studies found a statistically significant association/correlation between at least some of 
the studied clinical parameters (PD, CAL, and BOP for example). Altogether 86% of 
studies comparing MMP-8 levels between healthy and periodontitis sites (or pooled GCF 
from healthy and periodontitis patients) reported significantly increased MMP-8 levels 
in periodontitis sites or patients. On the other hand, only 56% of studies reported 
significantly higher GCF MMP-8 levels in periodontitis sites/patients compared to 
gingivitis.  
There are relatively few studies comparing GCF MMP-8 levels in progressive or the 
active sites to the stable periodontitis sites in the longitudinal cohorts. The vast majority 
of clinical trials listed in Table 1 were designed to study the treatment effect and not the 
disease progression or the detection of active sites.  The studies designed to study the 
association between the active sites or the disease progression and GCF MMP-8 are listed 
in Table 3. One study out of five could found no significant difference in GCF MMP-8 
levels between active/progressive and stable sites as the rest of studies reported 
increased MMP-8 levels in active/progressive periodontitis sites (Table 3).  
The vast majority of the studies analyzed differences between periodontal disease 
groups and controls with statistical tests and reported p-values. Few studies reported the 
diagnostic performance of GCF MMP-8, also with sensitivity/ specificity, odds ratios, or 
likelihood ratios (Table 1 and Table 2) (Mäntylä et al. 2003, Kim et al. 2014). 
 41
 
  T
ab
le
 1
. E
ffe
ct
 o
f p
er
io
do
nt
al
 tr
ea
tm
en
t o
n 
GC
F 
M
M
P-
8 
le
ve
ls
 in
 c
lin
ic
al
 tr
ia
ls
  
Au
th
or
 
    
   Y
ea
r 
N
 o
f 
pa
ti
en
ts
   
x 
(s
it
es
) 
 T
he
 E
ff
ec
t 
of
 S
R
P 
tr
ea
tm
en
t 
+ 
 
po
ss
ib
le
 a
dj
un
ct
iv
e 
tr
ea
tm
en
t 
M
M
P-
8 
d
et
ec
ti
on
 
m
et
h
o
d 
A
dd
it
io
n
al
 
in
fo
rm
at
io
n
 
al
o
ne
 
LD
D
 
O
th
er
   
Su
om
al
ai
ne
n
 
19
92
 
 
(+
) 
 
 
Co
lla
ge
na
se
 a
ct
iv
it
y 
 
G
ol
ub
 e
t 
al
. 
19
97
 
18
 x
 (8
-1
2)
 
- 
+ 
 
Co
lla
ge
na
se
 a
ct
iv
it
y 
 
Sa
id
 e
t 
al
. 
19
99
 
32
 x
 (2
-3
) 
 
 
(-
) 
IF
M
A
 
Su
rg
er
y 
+ 
bi
om
em
br
 
+ 
am
ox
ic
ill
in
 2
g 
A
sh
le
y 
et
 a
l. 
19
99
 
75
 (1
71
) 
- 
+ 
 
Co
lla
ge
na
se
 a
ct
iv
it
y 
 
So
rs
a 
et
 a
l. 
19
99
 
(3
1)
 
+ 
 
 
IF
M
A
 
 
Ch
en
 e
t 
al
. 
20
00
 
16
 x
 (7
-1
6)
 
+ 
 
 
IF
M
A
 
 
O
ku
da
 e
t 
al
. 
20
01
 
36
 
 
 
+ 
E
LI
SA
 (
A
m
er
sh
am
) 
Su
rg
er
y 
+ 
em
do
ga
in
 
A
zm
ak
 e
t 
al
. 
20
02
 
20
 x
 (2
) 
- 
 
+ 
IF
M
A
 
SR
P 
+ 
CH
X 
ch
ip
 
B
ud
un
el
li 
et
 a
l. 
20
02
 
22
 
+ 
 
+ 
IF
M
A
 
SR
P 
+ 
m
el
ox
ic
am
 
Pe
rs
so
n 
et
 a
l. 
20
03
 
30
 x
 (3
) 
 
 
(+
) 
E
LI
SA
 
Su
rg
er
y 
 42
 
 K
in
an
e 
et
 a
l. 
20
03
 
20
 x
 (4
) 
+ 
 
 
IF
M
A
 
 
Le
e 
et
 a
l. 
20
04
 
41
 x
 4
 
- 
- 
 
EL
IS
A
 (A
m
er
sh
am
) 
 
Fi
gu
er
ed
o 
et
 a
l. 
20
04
 
64
 x
 (5
-6
) 
+ 
 
 
EL
IS
A
 (Q
ua
nt
ik
in
e)
 
 
Em
in
gi
l e
t 
al
. 
20
04
 
20
 
+ 
+ 
 
IF
M
A
 
 
M
än
ty
lä
 e
t 
al
. 
20
04
 
19
 
(+
) 
 
 
IF
M
A
 
 
Ch
oi
 e
t 
al
. 
20
04
 
32
 
(-
) 
+ 
 
EL
IS
A
 (A
m
er
sh
am
) 
 
Q
ad
ri
 e
t 
al
. 
20
05
 
34
 
 
 
(-
) 
 
SR
P+
 la
se
r 
Po
zo
 e
t 
al
. 
20
05
 
13
 (6
0)
 
(+
) 
 
 
Co
lla
ge
na
se
 a
ct
iv
it
y 
+ 
W
B
 
 
M
än
ty
lä
 e
t 
al
. 
20
06
 
16
 (1
32
) 
+ 
 
 
IF
M
A
 
 
A
ğa
n 
et
 a
l. 
20
06
 
10
 (3
2)
 
+ 
 
+ 
E
LI
SA
 (
Q
ua
nt
ik
in
e)
 
SR
P 
+ 
CH
X
 
Ku
rt
is
 e
t 
al
. 
20
07
 
58
 
+ 
 
+ 
E
LI
SA
 (
Q
ua
nt
ik
in
e)
 
SR
P+
 N
SA
ID
 
Q
ad
ri
 e
t 
al
. 
20
07
 
40
 
 
 
- 
E
LI
SA
 (
Q
ua
nt
ik
in
e)
 
SR
P 
+ 
La
se
r 
Co
rr
ea
 e
t 
al
. 
20
08
 
46
 x
 (5
-6
) 
(+
) 
 
 
E
LI
SA
 (
R
&
D
) 
M
M
P-
8 
re
du
ct
io
n 
on
ly
 in
 d
ee
p 
po
ck
et
s 
G
ol
ub
 e
t 
al
. 
20
08
 
64
 x
2 
 
(+
) 
 
W
es
te
rn
bl
ot
 
 
H
er
na
nd
éz
 e
t 
al
. 
20
10
 
50
 
+ 
 
 
IF
M
A
 
 
 43
 
 Q
ad
ri
 e
t 
al
. 
20
10
 
60
 
(+
) 
 
(+
) 
E
LI
SA
   
   
   
   
   
   
  
(S
ys
te
m
s 
E
ur
op
e)
 
SR
P+
 la
se
r 
Tu
te
r 
et
 a
l. 
20
10
 
58
 (3
48
) 
+ 
+ 
 
EL
IS
A
 
 
M
ar
ca
cc
in
i e
t 
al
. 
20
10
 
42
 
+ 
 
 
EL
IS
A
 
 
B
as
eg
m
ez
 e
t 
al
. 
20
11
 
16
0 
+ 
 
+ 
E
LI
SA
 
SR
P 
+ 
M
in
oc
yc
lin
 
H
an
 e
t 
al
. 
20
12
 
28
 
+ 
 
+ 
IF
M
A
 
SR
P+
 A
zi
th
ro
m
yc
in
 
G
ilo
w
sk
i e
t 
al
. 
20
12
 
34
 
- 
 
+ 
EL
IS
A
 (Q
ua
nt
ik
in
e)
 
 
El
ta
s 
&
 O
rb
ak
 
20
12
 
40
 
+ 
 
+ 
E
LI
SA
 (
A
m
er
sh
am
) 
SR
P 
+ 
La
se
r 
Ko
no
pk
a 
et
 a
l. 
20
12
 
51
 
+ 
 
 
EL
IS
A
 (A
m
er
sh
am
) 
 
Em
in
gi
l e
t 
al
. 
20
12
 
32
 
+ 
 
+ 
IF
M
A
 
SR
P+
 A
zi
th
ro
m
yc
in
 
G
on
ça
lv
es
 e
t 
al
. 
20
13
 
29
 (5
8)
 
 
 
+ 
Fl
uo
ro
m
et
ri
c 
as
sa
y 
SR
P+
 a
nt
ib
io
ti
c 
Fa
rh
ad
 e
t 
al
. 
20
13
 
39
 (1
17
) 
- 
+ 
+ 
EL
IS
A
 (R
&
D
) 
 
Q
ue
ir
oz
 e
t 
al
. 
20
13
 
20
 (4
0)
 
- 
 
- 
M
M
P-
8 
(Q
ua
nt
ik
in
e)
 
SR
P 
+ 
La
se
r 
A
lv
es
 e
t 
al
. 
20
13
 
62
 x
 4
 
+ 
 
 
B
io
-P
le
x 
as
sa
y 
 
Ö
zg
ör
en
 e
t 
al
. 
20
14
 
32
 x
 4
 
- 
 
+ 
E
LI
SA
 
SR
P+
N
SA
ID
 
Ki
nn
ey
 e
t 
al
. 
20
14
 
10
0 
+ 
 
 
Cy
to
ki
ne
 A
rr
ay
 
R
ay
bi
ot
ec
h 
 
 44
 
 S
ag
la
m
 e
t 
al
. 
20
14
 
30
 
+ 
 
+ 
R
ay
bi
ot
ec
h 
SR
P 
+ 
La
se
r 
Po
ur
ab
ba
s 
et
 a
l. 
20
14
 
22
 x
 2
 
- 
 
- 
E
LI
SA
 
SR
P 
+ 
La
se
r 
Ts
al
ik
is
 e
t 
al
. 
20
14
 
66
 
+ 
+ 
 
EL
IS
A
 (Q
ua
nt
ik
in
e)
 
 
Si
gn
if
ic
an
t 
G
CF
 M
M
P
-8
 d
ec
re
as
e 
   
   
   
   
   
   
   
 
(+
) 
af
te
r 
tr
ea
tm
en
t  
26
 (
72
%
) 
8 
(8
9%
) 
16
 (
76
%
) 
 
 
N
o
 s
ig
ni
fi
ca
nt
 c
ha
ng
e 
in
 G
CF
 M
M
P
-8
 le
ve
ls
   
   
 
( -
) a
ft
er
 t
re
at
m
en
t 
10
 (
26
%
) 
1 
(1
1%
) 
5 
(2
4%
) 
 
 
T
he
 e
ff
ec
t 
of
 t
re
at
m
en
t 
on
 G
CF
 M
M
P
-8
 le
ve
ls
 is
 in
di
ca
te
d 
w
it
h 
+/
- 
si
gn
s.
  T
he
 +
 s
ig
n 
in
di
ca
te
s 
si
gn
if
ic
an
t 
M
M
P
-8
 d
ec
re
as
e 
af
te
r 
th
e 
tr
ea
tm
en
t. 
T
he
 –
 s
ig
n 
in
di
ca
te
s 
no
 s
ig
ni
fi
ca
nt
 c
ha
ng
e 
in
 t
he
 M
M
P-
8 
le
ve
ls
, r
es
pe
ct
iv
el
y.
  
 (
+/
-)
 s
ig
n 
w
it
hi
n 
th
e 
br
ac
ke
ts
 i
nd
ic
at
es
 
co
nt
ro
ve
rs
y 
in
 r
es
ul
ts
 45
 
 Ta
bl
e 
2.
 C
ro
ss
-s
ec
ti
on
al
 c
as
e-
co
nt
ro
l 
as
so
ci
at
io
n 
st
ud
ie
s 
an
d 
co
rr
el
at
io
n 
st
ud
ie
s 
of
 G
CF
 M
M
P-
8 
an
d 
cl
in
ic
al
 p
ar
am
et
er
s 
or
 d
is
ea
se
 s
ev
er
it
y 
St
u
d
y 
Ye
ar
 
N
 o
f 
pa
ti
en
ts
  
(x
 s
it
es
) 
 Co
rr
el
at
io
n 
w
it
h
 c
lin
ic
al
 
pa
ra
m
et
er
s 
Si
gn
if
ic
an
t 
di
ff
er
en
ce
 
be
tw
ee
n
**
 
M
M
P-
8 
d
et
ec
ti
on
 
m
et
h
o
d 
A
dd
it
io
n
al
 
in
fo
rm
at
io
n
 
H
 v
s.
 P
 
G
 v
s.
 P
 
Le
e 
et
 a
l. 
19
95
 
58
 
+ 
 
+ 
Co
lla
ge
na
se
 a
ct
iv
it
y 
 
H
al
in
en
 e
t 
al
. 
19
96
 
9 
 
(-
) 
 
Co
lla
ge
na
se
 a
ct
. &
 W
B
 
 
In
gm
an
 e
t 
al
. 
19
96
 
34
 
 
+ 
 
EL
IS
A
 
 
N
om
ur
a 
et
 a
l. 
19
98
 
21
 
(+
) 
(+
) 
 
Co
lla
ge
na
se
 a
ct
. &
 W
B
 
 
Sö
de
r 
19
99
 
40
 x
 4
 
+ 
 
 
 
 
M
an
ci
ni
 e
t 
al
. 
19
99
 
16
3 
(+
) 
(+
) 
(+
) 
B
io
ti
ny
la
te
d-
co
lla
ge
n 
as
sa
y 
 
R
om
an
el
li 
et
 a
l. 
19
99
 
19
+2
5 
(+
) 
(+
) 
(+
) 
B
io
ti
ny
la
te
d-
co
lla
ge
n 
as
sa
y 
 
Ch
en
 e
t 
al
. 
20
00
 
16
 
+ 
 
 
IF
M
A
 
 
A
ti
lla
 e
t 
al
. 
20
01
 
39
x2
 
(+
) 
 
 
IF
M
A
 
Cy
cl
os
po
ri
n 
m
ed
. 
 46
 
 
Ki
ili
 e
t 
al
. 
20
02
 
12
 
+ 
 
 
W
B
 
 
M
än
ty
lä
 e
t 
al
. 
20
03
 
29
 (2
07
) 
 
+ 
+ 
IF
M
A
 
 
U
llb
ro
 e
t 
al
. 
20
04
 
28
 
 
(+
) 
 
EL
IS
A
 
Pa
p.
 L
ef
ev
re
 v
s.
 
co
nt
ro
l 
Po
zo
 e
t 
al
. 
20
05
 
24
 (8
4)
 
+ 
 
 
Co
lla
ge
na
se
 a
ct
iv
it
y 
&
 
W
B
 
 
Fi
gu
er
ed
o 
et
 a
l. 
20
05
 
11
0 
 
 
(-
) 
EL
IS
A
 (Q
ua
nt
ik
in
e)
 
G
in
gi
vi
ti
s 
vs
 
sh
al
lo
w
 p
oc
ke
ts
 
Sö
de
r 
et
 a
l. 
20
06
 
64
x4
 
+ 
 
 
EL
IS
A
 (A
m
er
sh
am
) 
 
Pa
ss
oj
a 
et
 a
l. 
20
08
 
64
x2
 
(+
) 
 
 
EL
IS
A
 (Q
ua
nt
ik
in
e)
 
Sh
al
lo
w
 p
oc
ke
ts
 
Pr
es
ch
er
 e
t 
al
. 
20
07
 
64
 
 
(+
) 
(+
) 
D
en
to
A
na
ly
ze
r 
&
 IF
M
A
 
 
A
lfa
nt
 e
t 
al
. 
20
08
 
84
 (1
44
) 
 
+ 
 
Co
lla
ge
no
ly
ti
c 
ac
ti
vi
ty
 
 
B
ild
t 
et
 a
l. 
20
08
 
20
 
 
+ 
 
M
M
P 
ac
ti
vi
ty
/ 
zy
m
og
ra
ph
y 
 
Em
in
gi
l e
t 
al
. 
20
08
 
14
3 
(3
36
) 
+ 
 
 
IF
M
A
 
Ta
cr
ol
im
us
 m
ed
 
Te
le
s 
et
 a
l. 
20
09
 
40
 (9
31
) 
 
- 
 
Ch
ec
ke
rb
oa
rd
 
 
B
iy
ik
oğ
lu
 e
t 
al
. 
20
09
 
74
 (1
48
) 
 
+ 
- 
IF
M
A
 
 
 
 
 
 
 
 
 
 
 47
 
 A 
si
gn
if
ic
an
t 
as
so
ci
at
io
n/
co
rr
el
at
io
n 
be
tw
ee
n 
th
e 
M
M
P
-8
 l
ev
el
s 
an
d 
st
ud
ie
d 
cl
in
ic
al
 p
ar
am
et
er
s 
is
 i
nd
ic
at
ed
 w
it
h 
+ 
si
gn
 a
nd
 n
o 
as
so
ci
at
io
n 
w
it
h 
– 
si
gn
s,
 r
es
pe
ct
iv
el
y.
 A
 s
ig
n 
w
it
hi
n 
br
ac
ke
ts
 in
di
ca
te
s 
a 
co
nt
ro
ve
rs
y 
in
 r
es
ul
ts
. H
ea
lt
hy
 (H
),
 g
in
gi
vi
ti
s 
(G
),
 p
er
io
do
nt
it
is
 
(P
).
M
ar
ca
cc
in
i e
t 
al
. 
20
10
 
42
 
+ 
+ 
 
EL
IS
A
 
 
Te
le
s 
et
 a
l. 
20
10
 
40
 (9
31
) 
+ 
- 
 
Ch
ec
ke
rb
oa
rd
 
 
Ka
rd
eş
le
r 
20
10
 
73
 (1
46
) 
 
+ 
- 
IF
M
A
 
 
R
ai
 e
t 
al
. 
20
10
 
20
 x
 (1
-4
) 
 
+ 
 
EL
IS
A
 
 
R
ai
 e
t 
al
. 
20
12
 
10
7 
(4
08
) 
 
+ 
 
EL
IS
A
 (Q
ua
nt
ik
in
e)
 
 
Kr
af
t-
N
eu
m
är
ke
r 
et
 a
l.  
20
12
 
9 
(9
2-
 
11
2)
 
+ 
 
 
IF
M
A
 
 
Ko
no
pk
a 
et
 a
l. 
20
12
 
51
 
 
+ 
 
EL
IS
A
 
 
H
an
 e
t 
al
. 
20
12
 
31
4 
 
+ 
 
EL
IS
A
 
 
Ya
ko
b 
et
 a
l. 
20
13
 
99
 (3
96
) 
(+
) 
 
- 
IF
M
A
 
A
ss
o
c.
 w
it
h 
T.
De
nt
ic
ol
a 
A
lv
es
 e
t 
al
. 
20
13
 
62
 (2
48
) 
 
+ 
 
B
io
-P
le
x 
  a
ss
ay
 k
it
 
 
Ki
m
 e
t 
al
. 
20
14
 
50
6 
 
+ 
 
EL
IS
A
 (R
&
D
) 
 
Si
gn
if
ic
an
t 
co
rr
el
at
io
n
/ 
as
so
ci
at
io
n 
(+
) 
16
 
18
 (
86
%
) 
5 
(5
6%
) 
 
 
N
o 
co
rr
el
at
io
n
/ 
as
so
ci
at
io
n
 (
-)
 
0 
3 
(1
4%
) 
4 
(4
4%
) 
 
 
 48 
 
P-values fail to clarify diagnostic utility because they are affected by both, the 
differences between the group and the sample size in the study. The sensitivity and 
specificity are probably the most common statistical measures used to measure 
diagnostic performance. The measures of sensitivity and specificity are affected by a 
chosen cutoff.  The ROC analysis provides a relationship between true (sensitivity) and 
false positives (1-specificity) with different cutoffs. Odd ratios, likelihood ratios, and 
positive and negative predictive values are other possible measures that provide 
information about the diagnostic utility of GCF biomarkers.   
One additional PubMed search (“periodontal disease” and “MMP-8” and “sensitivity 
and specificity”] was performed to find articles with diagnostic performance calculations, 
also for the utility of saliva MMP-8 in periodontal diseases; 17 articles were found with 
the search. After checking manually, results of 13 original articles were further reviewed. 
Reviewed articles are listed in Table 4. Most of the listed articles studied the diagnostic 
utility of saliva or GCF MMP-8 to differentiate periodontitis from healthy and/or 
gingivitis sites but also a few longitudinal studies were found that had been designed to 
study the disease progression and the predictive utility of MMP-8, the therapeutic 
response in MMP-8 levels, and in one study the combination of different salivary 
biomarkers were analyzed in experimental gingivitis (Table 4).  
In all listed articles, increased GCF or saliva MMP-8 associated significantly with 
periodontitis. Reported AUC varied from 0.633 to 0.806, suggesting a moderate 
performance of the test (Fischer et al. 2003). Only one study reported AUC or odds ratio 
for smokers and non-smokers separately and showed better diagnostic performance for 
the non-smokers (AUC NS 0.81 vs. S 0.63) (Gürsoy et al. 2010a). Kinney et al. (2014) 
compared and combined clinical measures, microbial markers, and host-response 
biomarkers. GCF biomarkers provided a high specificity but a low sensitivity to predict 
disease progression. Conversely, salivary biomarkers demonstrated a high sensitivity but 
a low specificity (Kinney et al. 2014). The sensitivity and specificity were more in balance 
and reached to 70 and 71% by combining the salivary, GCF, the clinical, and the bacterial 
measures. Within the same data, salivary MMP-8 had 69% sensitivity and 70% specificity 
(AUC 0.75) to differentiate periodontitis patients from patients without periodontitis and 
the combination of MMP-8, IL-1?, T. denticola and P. intermedia could provide AUC up to 
a high accuracy of 0.93 (Ramseier et al. 2009). 
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As a conclusion from reviewed studies of GCF MMP-8, there is a clear association 
between increased MMP-8 levels and disease severity, and GCF MMP-8 can differentiate 
between healthy and periodontitis sites. Results indicating the difference between 
gingivitis and periodontitis are more variable but there is also a trend toward higher GCF 
MMP-8 in periodontitis sites compared to gingivitis, as was concluded also by Kinane et 
al. (2011). There is a clear decrease in GCF MMP-8 levels in most of the studies after 
successful periodontal treatment and the decrease is more probable with the adjunctive 
LDD treatment.   
Studies comparing different biomarkers highlight MMP-8 repeatedly, together with 
IL-1?, MPO, and elastase as the best performing diagnostic marker (Uitto et al. 2003, 
Hernandez et al. 2010, Kinane et al. 2011, Kinney et al. 2014). In addition, RANKL, OPG 
and ICTP, related to bone resorption and metabolism, can have utility for periodontal POC 
diagnostics (Reinhardt et al. 2010, Kinane et al. 2011). However, there is a large 
variability in detected GCF MMP-8 levels at both healthy and diseased periodontal sites. 
Especially low GCF MMP-8 levels at diseased periodontitis sites can overlap with levels 
detected from gingivitis or healthy sites producing false negatives and decreasing the 
specificity of diagnostic MMP-8 screening tests. Similarly, gingivitis sites can occasionally 
express relatively high GCF MMP-8 levels producing false positives (Mäntylä et al. 2003, 
Teles et al. 2009, Teles et al. 2010, Kinney et al. 2014) 
Many studies also found no significant change in GCF MMP-8 levels after treatment, 
whichindicates variability in GCF MMP-8 response patterns after treatment (Table 1), 
and also possibly variability between different MMP-8 detection methods (Leppilahti et 
al. 2011) 
Kinane et al. (2011, Consensus of the Seventh European Workshop on 
Periodontology) reviewed whether there are biomarkers fulfilling the above described 
five categories for the diagnostic biomarkers. They concluded that there is no biomarker 
available to distinguish those who are susceptible to periodontitis. For diagnostic 
purposes, there is some evidence for MMP-8 and MPO to distinguish between gingivitis 
and periodontitis, and RANKL/OPG system-related markers. ICPT, prostaglandin E2, ? 
glucuronidase, oncostatin M, cathepsin B, and cathepsin K could also be potential 
markers for diagnostic purposes. However, there is no marker available, which could 
differentiate between chronic and aggressive periodontitis. No biomarker could be found 
to provide this prognostic utility, but “there is limited evidence” for certain molecules to 
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be able to predict future disease progression. The response to periodontal treatment can 
be seen as decreased levels of many inflammatory markers and could be used for 
therapeutic purposes. (Kinane et al. 2011) 
 
Table 3. Studies comparing GCF MMP-8 levels between the progressive/active and 
the stable sites in longitudinal studies 
Author Author 
N of 
patients 
(sites) 
Difference 
between  
active and 
stable sites MMP-8 detection method 
Lee et al. 1995 58 + Collagenase activity & WB 
Mancini et al. 1999 163 + Biotinylated-collagen assay 
Reinhardt et al. 2010 128 + WB 
Hernandez et al. 2010 (50) (-) IFMA 
Kinney et al. 2014 100 + Cytokine Array Raybiotech 
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2. AIMS AND HYPOTHESIS OF THE STUDY 
 MMP-8 is a promising oral fluid biomarker and an option for periodontal point-of-
care diagnostics. Oral fluid MMP-8 levels have been reported to associate with the 
severity of periodontal diseases and clearly decrease after periodontal treatments. 
However, there has been a quite large variability in the oral fluid MMP-8 levels, which 
complicates diagnostic interpretations. Large variability can be caused via 
methodological, a host-related constitutional, or an environmental reason, manifested as 
variability between and within patients and periodontal sites. The general aim of this 
study is to evaluate the utility of GCF MMP-8 at the site-level periodontal POC diagnostics 
and to define different methodological and host-related reasons for the large statistical 
variability in detected GCF MMP-8 levels. The study hypotheses are: first, Analyses of GCF 
MMP-8 levels can be utilized in periodontal POC diagnostics; second, there is variability 
in detection levels between methods based on different MMP-8 antibodies.  
The specific aims of this study are:  
1. To compare the laboratory and point-of-care detection methods for measuring GCF 
MMP-8 levels (I, II).  
2. To compare cross-sectional correlations between GCF, MMP-8 and other biomarkers 
(MMP-13, -14, MPO, Azurocidin, CXCL-5) in healthy, gingivitis, and chronic 
periodontitis sites (II) 
3. To study patient effect on detected MMP-8 levels in site-level GCF study (II, III). 
4. To study longitudinal variability by exploring different site- level GCF MMP-8 
response patterns after non-surgical periodontal treatment in smoking and non-
smoking chronic (III, IV) and aggressive periodontitis (IV) patients with cluster 
analysis  
5. To characterize the clinically stable and unstable periodontitis sites and different site-
level clinical treatment outcomes during the maintenance treatment period (I, III, IV) 
for testing the GCF MMP-8 diagnostic and prognostic utility. 
6. To study the site-level diagnostic utility of GCF MMP-8 levels:     
i. Cross-sectional differentiation between healthy or gingivitis sites and 
periodontitis (II) 
ii. Prognostic utility to identify different treatment outcomes (III, IV) 
iii. Therapeutic utility for quantitative monitoring of treatment outcomes (III, IV). 
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3. MATERIAL AND METHODS 
 
3.1. Patients and periodontal sites 
 
Study I  
Inclusion criteria: 
1.  Moderate to severe chronic periodontitis diagnosed according to the criteria of 
the 1999 International World Workshop. 
2.  At least 20 teeth, at least five sites ≥ 4mm PD and radiographic bone loss. 
Six untreated moderate to severe chronic-periodontitis patients, two periodontally 
healthy and two gingivitis control patients were selected from the larger scale 
longitudinal study arranged in the clinic of the Institute of Dentistry, University of 
Helsinki, Finland in 1998-2000 (Mäntylä et al. 2003, 2006). One representative 
periodontal site was chosen for GCF sampling from each periodontitis patient. GCF 
samples were collected and clinical parameters recorded at baseline, at the post- 
treatment control visit approximately 1 month after the treatment, and at the 
maintenance treatment visits at two-month intervals during the 12 month follow-up.  In 
total, 45 GCF samples were collected from periodontitis patients at 7 to 8 follow-up visits; 
38 GCF samples from 2 periodontally healthy (20 samples) and two gingivitis (18 
samples) control patients were collected once at baseline. The baseline characteristics of 
studied sites are presented in the original article (I, Table 1). 
Study II 
Inclusion criteria:  
1.  Moderate to severe chronic periodontitis patients according to the criteria of 
the 1999 International World Workshop.  
2. At least 14 teeth, including at least 10 posterior teeth.  At least 5 sites with PD ≥ 
5 mm and CAL ≥ 3 mm, and detectable bone loss in radiographs. 
3.  Criteria for gingivitis control patients were inflamed gingiva and BOP with no 
signs of attachment loss. Criteria for healthy controls were PD < 3 mm and no 
CAL or BOP. 
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 Eight untreated patients with moderate to severe chronic periodontitis, 9 healthy, and 
6 gingivitis control patients took part to this cross sectional study. Patients were 
recruited from the Center of Diagnostics and Treatment of Northern Metropolitan Health 
Services, Santiago, Chile in 2010. A total of 58 GCF samples were collected from all 
patients [20 healthy (from 1 to 3 sites/patient), 19 gingivitis (from 1 to 4 sites/ patient), 
19 CP (from 1 to 4 sites/patient)]. Patient demographics are presented in the original 
article (II, Table 1) 
Study III  
Inclusion criteria:   
1. Moderate to severe CP diagnosed according the criteria of the 1999 
International World Workshop. 
2. At least 20 teeth, at least five sites ≥ 4mm PD, and radiographic bone loss. 
Altogether 15 untreated patients with moderate to chronic periodontitis were 
recruited from the clinic of the Institute of Dentistry, University of Helsinki in 1998-2000. 
For each patient, 5 to 7 periodontal sites were monitored throughout this longitudinal 
study. All patients received the SRP treatment at the beginning and the maintenance 
treatments in the two months interval.  The longitudinal follow-up included the baseline 
visit, the post-treatment visit, and 4 to 6 maintenance visits with clinical measurements 
and GCF sampling.  The study data included 742 GCF samples from 97 periodontal sites.  
There is an error in the text of the attached original article (III, Material and Methods, p. 
251) related to the number of smokers and non-smokers and males and females. The 
correct baseline characteristics of studied patients and sites are presented in Table 5.  
Study IV 
Inclusion criteria:  The aim of the inclusion criteria was to ensure that all GCF 
samples were collected, and MMP-8 levels determined, with the same method. The 
original study designs also had to be similar (clinical trials with SRP) to explore 
differences in longitudinal GCF MMP-8 response patterns in the different datasets. Thus, 
the following inclusion criteria were defined: 
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1. Diagnosed periodontitis (CP or AgP). 
2.  GCF was sampled at all sites with the same method. A paper strip is held for 
30 seconds in the gingival crevice. 
3. The same monoclonal antibody and the IFMA method was used for the 
detection of MMP-8. 
4. Longitudinal study design (clinical trials) including the conservative 
periodontal treatment (SRP) for previously untreated periodontitis patients, 
followed by maintenance visits with regular biofilm removal and oral hygienic 
instructions. The length of the maintenance was required to be at least 6 
months. 
Four independent longitudinal datasets met the criteria. Three datasets comprise 
Turkish patients recruited from the Ege University, İzmir, Turkey (Department of 
Periodontology, School of Dentistry). One dataset with generalized aggressive 
periodontitis patients (G-AgP) and two dataset with chronic periodontitis patients. One 
dataset comprised Finnish chronic periodontitis patients recruited from the Institute of 
Dentistry, University of Helsinki. From the Finnish dataset, 74 periodontitis sites were 
included from 15 patients (from 2 to 7 sites/ patient). 
  From the Turkish datasets altogether 32 G-AgP and 52 CP patients were included. 
In the Turkish data, only one site/patient was sampled for GCF. Clinical measurements 
and GCF sampling were done at baseline, at the post-treatment visit 1 month after SRP 
treatment, and at the maintenance-treatment visits 3 and 6 months from the baseline.  
 Original inclusion criteria of individual included datasets in study IV were as 
follows: 
 Data 1   
 Severe, generalized aggressive periodontitis patients, a clinical trial with SRP + 
azithromycin or placebo, Izmir, Turkey 2004-2006:  
1. Severe generalized aggressive periodontitis.  
2. At least 16 teeth. >30 sites with ≥ 5 mm CAL and ≥2 sites with a PD ≥ 6 mm 
in each quadrant that had BOP (Emingil et al. 2012). 
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 Data 2  
 Severe generalized chronic periodontitis patients, clinical trial with SRP+ 
azithromycin or placebo, Izmir, Turkey 2004-2006): 
1.  Diagnosed severe generalized chronic periodontitis.  
2. At least 16 teeth, CAL level of ≥ 5 mm and PD of ≥ 6 mm on ≥ 8 teeth (≥ 3 
other than central incisors or first molars); 30% or more bone loss of the 
root length in radiographs (Han et al. 2012a). 
 Data 3  
 Moderate and severe chronic periodontitis patients, clinical trial with SRP + LDD or 
placebo, Izmir, Turkey 1999-2001):  
1.  Diagnosed moderate to severe chronic periodontitis.  
2. At least 14 teeth, at least eight pockets with ≥ 5 mm PD and ≥4 mm CAL, and 
radiographic evidence of moderate to severe chronic periodontitis. (Emingil 
et al. 2004) 
 Data 4  
 Moderate and severe chronic periodontitis patients, clinical trial with SRP, Helsinki, 
Finland 1998-2000):  
1. Diagnosed moderate to severe CP.  
2. At least 20 teeth, at least five sites ≥ 4mm PD and radiographic bone loss. 
(Mäntylä et al. 2006) 
 
 All studies/data (I, II, III and IV) in this thesis had similar common exclusion 
criteria: 
1. Any history of severe medical disorder or systemic disease 
2. Pregnancy 
3. Received antibiotics or other medicines or periodontal treatment within the 
past 4-6 months.  
In the Turkish clinical trials (IV) heavy smokers were excluded (smoking >10 cigarettes 
per day). In addition, hypersensitivity to tetracycline, doxycycline, or any type of 
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macrolide was an exclusion criteria in the Turkish trials (IV) due to the adjunctive 
medication with LDD or azithromycin.  
 The study protocols were approved by the ethics committee of the Institute of 
Dentistry, University of Helsinki, by the Ethics Committee of the Ege University School of 
Medicine, Izmir, Turkey, and by the institutional review board from the Faculty of 
Dentistry, University of Chile. Study patients gave informed consent to participate in the 
study.  
Table 5. Baseline demographics and clinical parameters in studies III and IV.  
 
Study III 
Study IV 
 Data 1 Data 2 Data 3 Data 4 
Demographics      
Disease type CP G-AgP CP CP CP 
N of patients 15 32 28 24 15 
N of sites 97 32 28 24 74 
Visits  6- 8 4 4 3 4 
GCF samples 742 128 112 72 296 
Gender, patients (sites)      
       Males 5 (32) 17 18 15 5 (25) 
       Females 10 (65) 15 10 9 10 (49) 
Smoking, patients (sites)      
       Non- smokers 5 (30) 17 16 14 5 (23) 
       Smokers 10 (67) 13 12 10 10 (51) 
Medication, patients 
(sites)      
       None 15 (97) 16 14 12 15 (74) 
       Azithromycin  16 14   
       LDD    12  
Age, mean (95% CI) 43 (41-45) 29 (27-31) 46 (44-48) 46 (43-49) 43 (41-46) 
Clinical parameters      
CAL, mean (95% CI)      
       Non- smokers 5.9 (4.7-7.0) 7.7 (7.0-8.5) 7.8 (6.9-8.6) 7.7 (6.8-8.5) 7.1 (6.0-8.1) 
       Smokers 4.9 (4.4-5.5) 8.2 (7.2-9.1) 7.4 (6.6-8.2) 7.8 (6.3-9.3) 5.7 (5.2-6.3) 
PD, mean (95% CI)      
       Non- smokers 6.1 (5.6-6.6) 7.1 (6.4- 7.8) 6.2 (5.7-6.7) 6.8 (6.2-7.4) 6.5 (6.0-7.1) 
       Smokers 5.5 (5.3-5.7) 7.5 (6.6-8.4) 5.8 (5.3-6.4) 6.9 (6.3-7.4) 5.8 (5.6-6.1) 
BOP% all teeth,  
mean (95% CI)      
       Non- smokers data not 
available 
81 (72-90) 75 (64-85) 75 (62-88) data not 
available        Smokers 75 (67-85) 57 (43-71) 73 (63-82) 
BOP% sampled sites, 
 mean (95% CI)      
       Non- smokers 100 100 100 100 100 
       Smokers 73 (62-84) 100 100 90 (67-100) 71 (58-84) 
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3.2.   Clinical periodontal examinations and treatments 
 
 Probing depth (PD), clinical attachment loss (CAL), bleeding on probing (BOP), and 
visible plaque (VP) was recorded from six sites around the teeth. In each sub-study all 
the clinical examinations, the GCF samplings, and the treatments were done by the same 
calibrated peridontologist (I: P.M., II: J. G. III: P.M. IV: P.M & B.H.). All the patients received 
scaling and root plaining treatment, in addition to oral hygiene instructions after baseline 
examinations and maintenance treatments according to the study plan. Study IV included 
data from the clinical trials testing the effect of low dose doxycycline (LDD) or 
azithromycin adjunctive to the conventional SRP treatment, as half of the patients 
received the medication and the other half placebo.  
   
3.3. GCF Sampling 
 
 Before GCF sampling, teeth were cleaned and the supragingival plaque was 
removed with a sterile curette; the surfaces of sampling sites were gently air dried, and 
isolated by cotton rolls. A filter-paper sampling strip was gently placed into the gingival 
crevice for 30 seconds, avoiding any bleeding from the gingiva. After the GCF sampling 
proteins in the paper strips were eluted into the buffer solution and frozen for the storage 
and transportation (samples form Helsinki) or strips were frozen directly in the test 
tubes and proteins eluted into the buffer solution afterwards in the laboratory (Turkish 
and Chilean data). The elution buffer contained 50 mM Tris-HCl pH 7.5, 0.2 M NaCl, 5 mM 
CaCl2, and 0.01% Tritón X-100 (II) or HEPES pH 7.4 (Mäntylä et al. 2003; I, III, IV) or 
20mM Tris HCl, pH 7.5, 0.5 M NaCl, 5 mM CaCl2, 50μM ZnCl2, 0.5% bovine serum albumin, 
0.05% sodium azide, and 20 mg/l DTPA (Hanemaaijer 1997, Turkish data, IV). No 
significant difference in MMP-8 levels was evident between assay runs with different 
assay buffers (non-published data). Both HEPES and Tris- HCl are suitable elution buffers 
in MMP-8 immunoassays (Hanemaajier et al. 1997, Mäntylä et al. 2003, 2006), but if 
MMP-8 activities are also to be measured, then Tris-HCl, ph 7.5-7.8 buffers are 
recommended (Golub et al. 2008, Reinhardt et al. 2010).   
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3.4. Biomarker detection methods 
 
3.4.1. MMP-8 time-resolved immunofluorometric assay (IFMA) 
   MMP-8 levels were measured with the quantitative time-resolved 
immunofluorometric assay (IFMA, Medix Biochemica Ab Oy, Finland) as described 
thoroughly by Hanemaaijer et al. (1997). The monoclonal MMP-8-specific antibodies 
8708 and 8706 were used as a catching antibody and a tracer antibody, respectively. The 
tracer antibody was labeled using europium-chelate. The assay buffer contained 20 mM 
Tris-HCl, pH 7.5, 0.5 M NaCl, 5 mM CaCl2, 50 mM ZnCl2, 0.5% bovine serum albumin, 
0.05% sodium azide, and 20 mg/l DTPA. Samples were diluted in the assay buffer and 
incubated for 1 h, followed by incubation for 1 h with the tracer antibody. The 
enhancement solution was added, and after 5 min fluorescence was measured using a 
fluorometer. (Hanemaajer et al. 1997)  
 
3.4.2. POC MMP-8 detection methods: dentoAnalyzer? and stick-test 
 The dentoAnalyzer® (DentoGnostics GmbH, Germany) is a portable bench-top 
device design to measure biomarker levels from oral fluids. It automatically runs the 
assay process, including liquid handling as well as displaying final outcomes calculated 
by a software program. The key component is a cartridge consisting of a liquid-handling 
module including all needed reagents for immunological reactions like a clinical sample, 
conjugate, wash buffers, and substrate and a reaction chamber containing six filters with 
positive and negative controls, where the immunological reactions take place (Munjal et 
al. 2007a). Two antibodies detecting specific epitopes of the antigens are used in a 
sandwich-based immunoassay technology known as antibody immuno columnor 
analytical process (ABICAB), which is based on an immunoaffinity filter design using flow 
through solid phase filters with extremely high binding potential (Hartmann et al. 1993, 
Stove et al. 1995, Cavuslu et al. 2003, Meyer et al. 2007). DentoAnalyzer® is based on the 
same monoclonal antibodies as the IFMA method. Methodology for the dentoAnalyzer® 
is described in more detail by Munjal et al. (2007).   
 The MMP-8 specific immunochromatographic dip–stick (Medix Biochemica Ab Oy, 
Finland) is a qualitative POC test. The test result is provided in 5 min and is estimated by 
eye as positive or negative (Mäntylä et al. 2003, 2006). The test involves two monoclonal 
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antibodies to human MMP-8 (the same as in IFMA and dentoAnalyzer®, 8708 and 8706). 
One is bound to blue latex particles to act as the detecting label. The other antibody is 
immobilized on a carrier membrane to catch label particles and indicate a positive result. 
When the eluted GCF sample liquid is placed in the dip area of the stick, liquid is absorbed 
and begins to flow up the dip- stick. If there is MMP-8 in the sample it binds to the 
antibody attached to the latex particles. The antibody-MMP-8 particles are carried by the 
liquid flow and detected by the catching antibody.  A positive test result, if the cutoff level 
is exceeded, will appear as a blue line. A second blue line confirms the correct 
performance of the test. The dip-stick test is based on the same monoclonal antibodies as 
the IFMA analysis (8708 and 8706).  
 
3.4.3. MMP-8 ELISA 
 The commercially available MMP-8 ELISA analysis was conducted according the 
manufacturer´s instructions (Biotrak ELISA system, GE Healthcare, Amersham, 
Berkshire, UK). Levels were obtained from a standard curve and expressed as ng per ml 
of eluted GCF.  
 
3.4.4. MMP-8 western blot 
The molecular forms of MMP-8 were detected by using the modified enhanced 
chemiluminescence (ECL) Western blotting kit according to the protocol recommended 
by the manufacturer (GE Healthcare, Amersham, UK) as described earlier (Hernandez et 
al. 2010). Briefly, the GFC samples were mixed with Laemmli’s buffer without any 
reducing reagents and heated for 5 min, followed by protein separation with 11% sodium 
dodecyl sulphate (SDS)-polyacrylamide gels. After electrophoresis, the proteins were 
electrotransferred onto nitrocellulose membranes (Protran®, Whatman GmbH, Dassel, 
Germany). Non-specific binding was blocked with 5% milk powder (Valio Ltd., Helsinki, 
Finland) in TBST buffer (10 mM Tris-HCl, pH 7.5, containing 22 mM NaCl and 0.05% 
Triton-X) for 1 h. The membranes were incubated with the monoclonal primary antibody, 
anti-8708 (Medix Biochemica Ab Oy, Finland) overnight, followed by the horseradish 
peroxidase-linked secondary antibody (GE Healthcare, Buckinghamshire, UK) for 1 h. 
The membranes were washed 4 times for 15 min in TBST between each step. The 
proteins were visualized using the ECL system and scanned and analyzed using GS-700 
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Imaging Densitometer Scanner (Bio-Rad, Hercules, CA, USA) and the Bio-Rad Quantity 
One program. 
 
3.4.5. Determination of MMP-13, MMP-14, TIMP-1, MPO, Azurocidin, and CXCL5 
Levels from GCF 
 Total levels and the portion of endogenous active MMP-13 and MMP-14 from eluted 
GCF were defined separately with or without adding aminophenylmercuricacetate 
(APMA, Sigma, St.Louis, MO, USA) into aliquots. The MMP-13 analysis was performed by 
using the Human Active MMP-13 Fluorokine E kit (R&D Systems, Inc. Minneapolis, USA), 
and MMP-14 analysis with the MMP-14 Biotrak activity assay system (GE Healthcare, 
Amersham), according to the manufacturer’s recommendations. Levels were obtained by 
interpolating from a standard curve and expressed ng per ml of eluted GCF (Hernandez 
et al. 2006, Hernandez et al. 2010). 
 Total levels of TIMP-1 (Biotrak ELISA system, GE Healthcare, Amersham, Slough, 
Berkshire, UK), MPO (Immundiagnostik, AG, Bensheim, Germany), azurocidin (Cusabio 
Biotech Co. Ltd, Wuhan, China) and CXCL5 (R&D Systems, Minneapolis, MN, USA), were 
determined with the commercial ELISA kits according manufacturer´s instructions. 
Levels were obtained by interpolating from standard curves. 
   
3.5. Statistical analysis 
 
3.5.1. Statistical comparisons of study groups 
Cross-sectional MMP-8 distributions appeared to be ubiquitously right skewed in all 
data sets in this thesis (I, II, III, IV) as has also been described elsewhere (Teles et al. 2009, 
Kraft-Neumärker et al. 2012, Kinney et al. 2014). Non–parametric methods, Wilcoxon 
signed rank test (for dependent variables), and Mann–Whitney U test and Kruskal-Wallis 
(for independent variables) were used for statistical comparisons between the study 
groups if the data normalization was not done (I, III). Non-parametric Spearman 
correlations were favored for skewed data. In study IV, mean and 95% confidence 
intervals of MMP-8 levels and clinical parameters were reported descriptively, as was 
also done for study III parameters in the summary part of the thesis to make the 
comparisons between studies III and IV easier, although in the original article of study 
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III, the MMP-8 levels and clinical parameters were given in medians and respective IQR 
was reported. In study II, log normalization was conducted on the MMP-8 levels and the 
other biomarkers not obeying the normal distribution to legitimize the use of the t-test, 
the ANOVA F test, and the regression model described below. Pearson chi –squared test 
was used in cross-tabulations. Statistical programs SPSS (IBM, NY, USA) and R 
(http://www.R-project.org) were used to conduct the analysis.  
 
3.5.2. Data normalization of the pooled data  
 In study IV, data was pooled from four independent datasets.  The data inclusion 
criteria were aimed to ensure that the GCF sampling and the detection of GCF MMP-8 
levels were performed with the same method. However, there are always discrepancies 
between assay runs in immunological detection methods, which can be seen as scalar 
differences (Holzel1991, Elshal & McCoy2006). Thus, the data in study IV was normalized 
into the same scale (from 0 to 1). The normalized level can be interpreted as a percentage 
measure from the population maximum. Before the normalization, MMP-8 distribution 
types were assessed to be similar in all the datasets and the procedure was determined 
to be eligible by analysing the distributions with quantile to quantile (Q-Q) plots (SPSS). 
The gamma distribution gave the best fit with GCF MMP-8 distributions in the data (Q-Q 
plots, Figure 2, Figure 3, non-published data). The Q-Q plot is a graphical method to 
compare distributions with each other. In this context, distributions from different 
datasets (empirical data) were compared to different test distributions (gamma, 
exponential, normal, log-normal etc.). 
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Figure 2. Q-Q plots of the original GCF MMP-8 levels (observed) compared to the 
gamma test distribution (expected) in four different datasets of the study IV. 
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Figure 3. Gamma Q-Q plots of the normalized GCF MMP-8 levels in study IV cross-
sectionally at the baseline; A) non- smokers and B) smokers defined separately. 
Estimated shape and scale parameters of gamma distribution for the smokers: 0.45 and 
4.97; and the non-smokers: 0.91 and 4.89 (non-published data). 
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3.5.3. Generalized mixed regression model 
A generalized mixed regression model was used to study the patient effect in the site-
level GCF study (II). The model allows hierarchical dependence and the clustering of 
samples (patient -> sites) in the data. The analyzed biomarker level was considered to be 
an outcome measure, the periodontal health status as an explaining fixed effect, and the 
patient as a random effect. The analysis were performed using the packages “nlme” and 
“lmerTest” in R (http://www.R-project.org/). An ANOVA F test and a post hoc t-test with 
a Bonferroni correction for an alpha level of 0.05 were used for comparing sites belonging 
to the healthy, the gingivitis, and the periodontitis groups. 
 
3.5.4. Receiver operating characteristics (ROC) analysis  
 ROC analysis was conducted to evaluate the diagnostic utility of MMP-8 levels in the 
cross–sectional setting (II) and to search the most optimal cutoff levels for the analysis of 
prognostic utility (III and IV).  In study II, a bayesian analyzing method was used to take 
the clustering of data into account. Three MCMC chains were used, and the burn-in phase 
was extended until convergence was met, as determined by the Gelman–Rubin statistic. 
The posterior distributions were calculated from a total of 10,000 samples. SPSS (III and 
IV) and the software JAGS, using R (II) were used to run the analysis.  
 
3.5.5. Cluster analysis 
A cluster analysis was used to explore the longitudinal site-specific MMP-8 response 
patterns (III and IV). For the analysis, the established k means method was employed 
with the correlation (Pearson) distance measure and 1000 replicate runs. The correlation 
(Pearson) distance measure, maximizing the correlation between longitudinal sections 
(response patterns) of different periodontal sites within the cluster, was used to 
emphasize the shape of the longitudinal response patterns (MMP-8 or CAL change.).  
Smokers and non-smokers were analyzed separately. The site level MMP-8 response 
patterns were clustered into two (k = 2, III) or into four groups (k = 4, IV) depending on 
the study size. Also, clinical treatment outcomes were categorized by using the same 
cluster analysis method in study III. Sites were clustered according to CAL change during 
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the maintenance period into two groups (k = 2). Statistics Toolbox of MATLAB program 
(MathWorks, Natick, MA) was used to conduct the cluster analysis.  
 
3.5.6. Analysis of prognostic utility 
The prognostic utility of GCF MMP-8 levels was tested by first defining the most 
optimal cutoff levels by maximizing the sum of sensitivity and specificity (the Youden 
index) at baseline (III and IV) and the maintenance period (IV) from ROC analysis and 
then cross tabulating the MMP-8 test positives and negatives against the categorical 
treatment outcomes (the weak/compromised or the successful treatment outcome, 
based on CAL change).  Pre- and post-test probability, negative and positive predictive 
values, and likelihood ratios were calculated from the cross–tabulations to evaluate the 
prognostic utility of MMP-8 levels. The prevalence of compromised clinical treatment 
outcomes was used as the pre-test probability at baseline. Statistical variability was 
indicated by 95% confidence intervals.  In the original article of study III, the term “weak” 
was used instead of “compromised” treatment outcome.  However, only the term 
“compromised”, which was used in study IV, is used for clarity in the summary part of 
this thesis, because it describes the clinical outcome better (see also 4.3. clinical 
treatment outcomes in longitudinal studies). 
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4. RESULTS 
 
4.1.  Cross-sectional variability in MMP-8 levels 
 
4.1.1. Differences between detection methods and comparison of POC methods  
 IFMA method correlated well with dentoAnalyzer® (correlation coefficient 0.95; 
Spearman correlation) and results of the qualitative dip-stick test was well in line with 
the quantitative IFMA and dentoAnalyzer® methods (I). The commercial MMP-8 ELISA 
did not correlate significantly (p > 0.05) with the IFMA, dentoAnalyzer® or dip-stick (I).  
On the other hand, there was significant correlation between the MMP-8 levels of IFMA 
and the commercial ELISA in study II (all sites: r = 0.87, p < 0.001, periodontitis sites: r = 
0.91, p < 0.05).  
 More detailed analysis of the GCF MMP-8 detection methods, commercial ELISA, 
IFMA, and the POC methods revealed that with the low GCF MMP-8 levels, the commercial 
ELISA, IFMA, and DentoAnalyzer® levels were at the same levels but at higher levels the 
commercial ELISA did not follow along with IFMA, as was the case with dentoAnalayzer® 
or the stick test in the study I (Table 6).   
 There were also differences between IFMA and ELISA in the correlation profile of 
MMP-8 and the other studied biomarkers. MMP-8 IFMA also had better discriminatory 
properties between periodontitis and gingivitis or healthy sites compared to the MMP-8 
ELISA method (II, Table 3 and 4).  
 There was a significant decrease in MMP-8 levels after SRP treatment and during 
the maintenance period if MMP-8 was measured with IFMA or dentoAnalyzer ®, instead 
the decrease was not statistically significant with the ELISA (Table 6).
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Table 6. Comparison of different MMP-8 detection methods in study I. 
Detection method, 
mean (range) ng/ml 
Baseline After treatment p value 
IFMA 5 900 (1 690- 13 400) 2 180 (457- 6 420) 0.028 
DentoAnalyzer 213 (17- 311) 61 (5- 311) 0.043 
Commercial ELISA 15.9 (1.8- 36.7) 10.5 (1.2- 17.6) >0.05 
 
 IFMA < 1000 * IFMA 1000- 4000  IFMA > 4000   
IFMA 487 (35- 877) 2 080 (1 200- 3 610) 9 250 (4 260- 18 100) <0.001 
DentoAnalyzer 5.1 (1- 13) 57.3 (7- 222) 309 (290- 311) <0.001 
Commercial ELISA 6.7 (2- 17.6) 8 (1.8- 17.5) 9.7 (0.6- 36.6) >0.05 
Test stick 
 % of pos. results 
11.8 43.8 100 <0.001 
* MMP-8 levels detected by the IFMA method are categorized into three category IFMA <1000 ng/ml, 1000-4000 ng/ml and >4000 
ng/ml, respectively, for comparison with other detection methods in the lower cross tabulation. 
  
 
4.1.2. Differences between healthy, gingivitis and periodontitis sites in MMP-8 
isoforms  
The activated, 55 kDa MMP-8 immunoreactive species were observed only in GCF 
samples from periodontitis sites in the western immune blot analysis based on the same 
monoclonal antibody (anti-8708, Medix Biochemica Ab Oy, Finland) as IFMA, 
dentoAnalyzer® or dip-stick test (I). On the contrary, gingivitis sites had mainly the 
latent (proform) 65 kDa species; as in healthy sites hardly any immunoreactivity was 
detected. The high molecular weight complexes (>100 kDa) and the fragmented species 
(30-40 kDa) were detected in both gingivitis and periodontitis sites (I, Figure 5).  
 
4.1.3. Cross sectional differences between healthy, gingivitis and periodontitis 
sites in GCF MMP-8 levels   
 Statistical comparisons between chronic periodontitis and healthy or gingivitis sites 
were performed in study II. Mean (95% CI) GCF IFMA MMP-8 levels in healthy, gingivitis 
and periodontitis sites were 40 (13-67), 115 (54-176), and 367 (250-484) ng/ml, 
respectively. The difference between periodontitis and gingivitis (p = 0.003) or healthy 
(p < 0.001) sites was significant.  In ANOVA, the variance between study groups (healthy, 
gingivitis, chronic periodontitis) explained 54% of the whole variance as within-group 
variance explained 46%.  
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4.1.4. Correlations between MMP-8 and the other GCF biomarkers  
 In periodontitis sites (II), there was a high correlation between the IFMA MMP-8 
levels and MPO (r = 0.95, p < 0.001), and significant correlation between IFMA MMP-8 
and MMP-13 levels (total levels: r = 0.55 and active: r = 0.59). In subjects with healthy 
periodontium, IFMA MMP-8 correlated significantly with azurocidin. In the gingivitis 
group, no significant correlations between MMP-8 IFMA and other biomarkers were 
found as MMP-8 ELISA levels correlated with MMP-14. Correlation coefficients and 
respective p-values between the different biomarkers are presented thoroughly in the 
original article (II).   
 
4.1.5. The patient effect on site level GCF MMP-8 levels 
 In site-level studies, there can be patient-related clustering of data if multiple sites 
per patient are included in the study. The patient effect was taken into account with 
mixed-regression model analysis (II). The patient effect size was approximately 13% 
from the whole variance explaining part of the “within” variance (46% from the whole 
variance). However, the (random) patient effect was insufficient to improve the accuracy 
of the used regression model and thus was discarded in further analysis.  
 In study III, the longitudinal variability of MMP-8 levels was evaluated. Site-level 
longitudinal GFC MMP-8 response pattern types were clearly gathered within the same 
patients (III, table 4).  In the smokers, 20 profile-1 sites were clustered into five patients, 
as the other five patients presented only one profile 1 site. Profile-2 sites were observed 
in all patients.  In the non-smokers sites, profile-3 sites were clustered into three patients 
(out of 5) as all the non-smokers had profile-4 sites.  Different response-pattern types are 
described in more detailed below, in the section 5.2. “longitudinal GCF response 
patterns”. (III).  
 
4.1.6. The effect of smoking on GCF MMP-8 variability  
 The effect of smoking was controlled in studies II, III, and IV. In studies III, and IV, 
smokers and nonsmokers were stratified separately. In study II, the smoking status could 
not be stratified due to a lower data size but the number of smoking patients was 
statistically equal in all groups.  There was a clear and statistically-significant difference 
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in the GCF MMP-8 levels between smoking and the non-smoking patients at baseline (III, 
IV). 
 In study III, mean (95% CI) GCF MMP-8 levels were 1360 (810-1920) ng/ml for the 
smokers and 4440 (3180-5690) ng/ml for the non-smokers at baseline. In study IV, the 
normalized mean (95% CI) level was 0.09 (0.06- 0.12) in the smokers, and 0.19 (0.14-
0.23) in the non-smokers, corresponding to 1640 (1090-2190) ng/ml and 3460 (2550-
4190) ng/ml in study III.  
 During the maintenance period (III, IV), non-smokers´ mean GCF MMP-8 levels 
decreased significantly and retained at lower levels, while the mean levels decreased in 
the smokers´ at first but then returned nearly to baseline levels (Figure 4). The mean 
MMP-8 levels were approximately at the same level (1000-2000 ng/ml) from 3 to 4 
months after SRP (III, IV), and no significant difference between the smokers and non-
smokers was detected later on during the maintenance period (Figure 4). Different types 
of MMP-8 response patterns, which could be explored via cluster analysis as described 
below, were evident for both non-smokers and smokers.  
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Figure 4 Mean (95% CI) GCF MMP-8 levels in the smokers and the non-smokers at different 
time points of studies III (A) and IV (B).  
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4.2. Longitudinal GCF MMP-8 response patterns 
 
 In study I, stable and unstable sites were defined according to clinical parameters 
and compared to MMP-8 levels. In the stable sites, mean CAL and PD levels decreased 
after SRP treatment together with the MMP-8 levels and both the clinical parameters and 
the MMP-8 levels retained at low levels during the maintenance period (I, Figure 1).  In 
unstable sites, PD decrease and CAL gain was lost soon after treatments and MMP-8 levels 
tended to increase or fluctuated during the maintenance period. 
 In studies III and IV, a similar longitudinal set-up was tested with the larger study 
sample, and the longitudinal GCF MMP-8 response patterns after SRP treatment were 
explored with cluster analysis. Smokers and the non-smokers were handled separately. 
In study III, sites were clustered into two groups, while in study IV, sites could be 
clustered into four groups due to the larger data.  The idea of the cluster analysis with 
varying numbers of clusters was to determine different response patterns, which are not 
observable in the overall mean levels (IV, Figure 1).  
 Both smokers and non-smokers could be clustered into two distinct groups 
according to their baseline GCF MMP-8 levels and response patterns during the 
maintenance period.  Characteristically, sites with high GCF MMP-8 levels at baseline (the 
Type I response pattern) presented the most obvious decrease after non-surgical 
periodontal treatment while sites with low GCF MMP-8 levels at baseline (the Type II 
pattern) demonstrated increasing levels in relative to baseline during the maintenance 
period (III, Figure 1; IV, Figure 1). In study III, the number of non-smoker sites and 
patients was low and the differentiation of patterns was unclear. However, two distinct 
groups could also be clustered among the non-smokers from the larger data in study IV. 
The smokers´ sites with type-II response patterns could be differentiated further into 
high- and low-responding sites according to the relative increase of GCF MMP-8 levels 
during the maintenance period. In an earlier study, the cutoff at 4000 ng/ml twice or 
more often during the maintenance period was used for the high-responders (Mäntylä et 
al. 2006). The sub-group of high-responders among smokers was also explored 
“agnostically”, without any presumptions, as an own group when the sites were clustered 
into four groups (IV, Figure 1). High-responders continuously displayed exceptionally 
high MMP-8 levels during the maintenance period.  Among the non-smokers, such a 
distinct group of high-responders could not be differentiated in the cluster analysis, but 
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there were individual sites with high MMP-8 levels during the maintenance period. The 
high MMP-8 levels increased the risk for compromised treatment outcome twice, or more 
often, during the maintenance period in the both smoking and non-smoking patients, as 
described below. 
  
4.3. Clinical treatment outcomes in longitudinal studies 
 
 In studies III and IV, cluster analysis was employed to explore general trends in CAL 
change during the maintenance period, to form a dichotomous “dummy” variable for 
testing the utility of GCF MMP-8 levels to give a prognosis for the respective clinical-
treatment outcome.  Cluster analysis works “agnostically” to explore groups with similar 
response patterns, whilst also maximizing difference between groups. However, there is 
no guarantee that the dichotomy produced by the clustering would have any clinical 
rationality. Thus, results were compared between the cluster analysis and the “consensus 
definition” of a significant CAL change (2 mm cutoff) at the end of the maintenance period. 
 In studies III and IV, two distinct groups were explored with cluster analysis in both 
smokers and non-smokers. The groups were given names ‘compromised’ or ‘successful’ 
according the trend in CAL change. There was a significant PD decrease after the 
treatment in most sites in both clusters, but the trend was that CAL change did not follow 
along with PD change in the group of compromised outcomes (Figure 5, and 6). There 
was a significant difference in CAL change (p<0.001) between the clusters of 
compromised and successful outcomes during the end of maintenance period (III and IV). 
Sites with compromised outcomes demonstrated less CAL gain, or there was no 
significant change in CAL when sites with successful outcome had significant CAL gain 
near the measures of PD decrease. In the smokers´ sites, the mean CAL gain was near zero 
in the group of compromised outcomes in the both studies (III and IV) when in the non-
smokers the mean CAL gain was between 1-2 mm in the group of compromised outcomes 
compared to successful outcomes, with 3-4 mm CAL gain at the end of maintenance.   
 When PD decrease, CAL gain, and gingival recession (GR) are presented together 
(Figure 5.), it appears to be quite obvious that in the sites with the compromised 
outcome, PD decrease is achieved more through GR, while in the sites with the successful 
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outcome, PD decrease and CAL gain is achieved through re-attachment of junctional 
epithelium (III, IV).  
When the cluster analysis and the consensus method of 2 mm (Haffajee et al. 1983) 
are compared it seems that the methods gave surprisingly similar results (Figure 6).  In 
study III, there was no significant difference in the mean CAL change whether the 
weak/compromised treatment outcome was defined with the cluster analysis or by using 
the cutoff of 2 mm mean CAL gain at the end of the maintenance period (6-12 months 
mean)  (Figure 6). Similarly, in study IV, there was no difference among the smokers in 
the comparison, respectively (cluster analysis vs. CAL gain > 2 mm after 6 months). 
Nevertheless, a more clinically rational differentiation was achieved by using the 2 mm 
cutoff compared to cluster analysis in non-smokers, and this approach was used for 
further analysis in study IV (Figure 6).  
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Figure 5. Clinical parameters and their changes in different categorical treatment 
outcomes (successful and compromised*) at different points in studies III and IV.   
*The divergence of PD decrease and CAL gain and larger gingival recession is presented 
in the groups of compromised treatment outcome. PD decrease and CAL gain are 
indicated with positive measure/sign and GR with negative sign. GR = gingival recession, 
PD = pocket depth, CAL = clinical attachment level.  
*In study III, the compromised and successful treatment outcome was determined with 
cluster analysis and in study IV, by the 2 mm cutoff at the end of the maintenance period 
(6 months). 
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Figure 6. Comparison of trend lines (mean, 95%CI) of categorical treatment 
outcomes defined either with the cluster analysis or the “consensus” 2 mm cut-off* 
in the studies III and IV. *In study III the site-specific mean CAL change was calculated 
from 6-12 months and sites with CAL gain ≥ 2 mm (negative CAL change) was categorized 
as successful, and < 2 mm as compromised, respectively. In study IV, which comprised 
less maintenance visits, the 2 mm cutoff was based only on the month six visit.  
 
4.4. Diagnostic and prognostic utility of GCF MMP-8 levels 
 
4.4.1. Diagnostic utility and screening performance of GCF MMP-8 and the other 
studied biomarkers  
 GCF MMP-8 (IFMA) levels could clearly discriminate (AUC: 0.97; 95% CI: 0.85-1) 
between periodontitis sites and gingivitis or healthy sites when the patient effect was 
taken into account (II). Other biomarkers could also differentiate between periodontitis 
and healthy sites: MPO (AUC: 0.98; 95% CI: CI 0.78–1), MMP-13 total (AUC: 0.94; 95%CI: 
0.72–1), MMP-14 total (AUC: 0.95; 95% CI: 0.78–1), Azurocidin (AUC: 0.90; 95%CI: 0.71–
1). Only MMP-8 and MPO, however, could differentiate significantly (p < 0.05) between 
periodontitis and both gingivitis and healthy sites (II). From the studied biomarkers, 
CXCL5, MMP-13 active, and MMP-14 active had no significant discriminatory properties 
between periodontitis and gingivitis or healthy sites (II).  Both MMP-8 IFMA and MMP-8 
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ELISA could discriminate between periodontal health status, but ELISA methods had 
lower ROC values and larger variability in the AUC score (AUC: 0.90; 95%CI: 0.54–1) 
compared to IFMA. The most optimal cutoff values, defined from the ROC curves and 
MMP-8 IFMA cutoffs, had a sensitivity of 0.95 and specificity of 0.94 as MMP-8 ELISA had 
0.89 sensitivity and 0.87 specificity, respectively 
 
4.4.2.  Prognostic utility of GCF MMP-8 levels 
The prognostic utility of GCF MMP-8 levels was analyzed by first determining the 
optimal cutoff levels to discriminate between the physiological and pathological GCF 
MMP-8 levels. The cutoffs were evaluated with ROC analysis: The GCF MMP-8 level with 
the highest discriminatory properties to differentiate between the clustered MMP-8 
response patterns, followed by clinical treatment outcomes (Table 7).  
In study III, two baseline-cutoff levels were defined for smokers, 770 ng/ml was the 
best level to discriminate between the two MMP-8 response patterns (profile/pattern 
type 1 and 2) as 160 ng/ml worked better to give the prognosis for the clinical treatment 
outcome.  Parameters evaluating the prognostic utility of MMP-8, when both cutoff levels 
were taken into account, are presented in the enclosed original article (III, Table 3). MMP-
8 levels > 770 ng/ml indicated a 22%-point risk increase (from 63% pretest probability 
to 85% post-test probability) for the compromised (weak) treatment outcome, as the 
levels below 160 ng/ml indicated 25%-point risk decrease (from 63% to 38%).  
In study III, the cutoff level of 4000 ng/ml differentiated high-responder sites from 
the low-responding-sites (pattern type 2 was named profile 2 in the original article, III) 
as described above. The 4000 ng/ml cutoff was also used in study I and was based on an 
earlier study by Mäntylä et al. (2006).  
In study IV, MMP-8 response patterns could be clustered into four groups when more 
sites and patients were included, allowing the distinct group of high-responders to be 
found among the smoking patients (IV, Figure 1). Thus, the most optimal cutoff could be 
sought for both the baseline and the maintenance period, to differentiate between 
physiological and pathological levels (Table 7). Among the smokers the most optimal 
common cutoff (for all time points) was found to be 0.045 (normalized level means 4.5% 
from the population maximum), which corresponds to 820 ng/ml in study III.  For non-
smokers, the level was slightly higher, 0.085, which corresponds to 1550 ng/ml, 
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respectively.  If all time points/visits were considered, the best cutoff level varied in range 
from 0.015 to 0.085 (from 270 to 1550 ng/ml) among the smokers and from 0.025 to 
0.085 (from 460 to 1550 ng/ml) among the non-smokers (Table 7).  
With the chosen 0.045 and 0.085 cutoffs, a positive test result indicated an 11%-point 
increase (from 49% pre-test probability to 60% post-test probability) at baseline, and 
the continuously detected high MMP-8 levels (the baseline and maintenance period) 
indicated a 39%-point increase (from 49% to 88%) for the smokers (IV). Among the non-
smokers, the increase of risk was 12%-points (from 25% to 37%) at baseline and 46%-
points for the continuously elevated levels (from 25% to 71%) (IV). All positive and 
negative likelihood ratios and post-test probabilities are presented in the original article 
(IV, Figure 3) 
 
Table 7. The ROC analysis of MMP-8 levels predicting different MMP-8 response 
patterns (clusters) or clinical treatment outcomes at different time points of study 
IV. Measures in the cells present the best cutoff levels (AUC; 95% CI).  
         parameter Baseline 1 month 3 months 6 months 
Smokers  k = 2 clusters 0.025 (0.92; 
0.87-0.97)* 
0.015 (0.60; 
0.46-0.74) 
0.035 (0.63; 
0.5-0.75) 
0.075 (0.66; 
0.54-0.79)* 
k = 4 clusters 0.085 (0.96; 
0.92-1)* 
0.015 (0.72; 
0.59-0.85)* 
0.065 (0.81; 
0.68-0.94)* 
0.065 (0.82; 
0.73-0.91)* 
Clinical 
treatment 
outcome  
0.055 (0.55; 
0.42-0.68) 
0.025 (0.67; 
0.54-0.80)* 
0.025 (0.73; 
0.62-0.84)* 
0.035 (0.67; 
0.55-0.79)* 
      
Non-
smokers 
 k = 2 clusters 0.085 (0.97; 
0.94-1)* 
0.015 (0.81; 
0.69-0.92)* 
0.045 (0.72; 
0.60-0.85)* 
0.035 (0.66; 
0.52-0.79) 
k = 4 clusters 0.085 (0.93; 
0.88-0.99)* 
0.025 (0.83; 
0.73-0.94)* 
0.045 (0.70; 
0.57-0.82)* 
0.035 (0.62; 
0.49-0.76) 
Clinical 
treatment 
outcome  
0.12 (0.78; 
0.66-0.90)* 
0.035 (0.81; 
0.69-0.93)* 
0.085 (0.76; 
0.61-0.91)* 
0.045 (0.75; 
0.63-0.86)* 
*statistically significant difference (p < 0.05).  
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5. DISCUSSION 
 
5.1. Random variability and statistical properties of GCF MMP-8 levels 
 
MMP-8 levels have expressed right-skewed distributions ubiquitously in all data 
sets in this thesis, as described in previous studies (Teles et al. 2009, Kinney et al. 2014, 
Kraft-Neumärker 2012, Mäntylä et al. 2006). Thus, levels below the mean value and 
extremely high “outliers” are more frequent as they were in a symmetric normal 
distributed data.  For example, mean MMP-8 level was 1360 ng/ml for smokers  at 
baseline and 4440 ng/ml for non-smokers and median levels were 362 ng/ml and 3620 
ng/ml, respectively (III). MMP-8 data gave the best fit with the gamma distribution in the 
data sets among both smokers and non-smokers. There is an interesting difference in the 
shape parameter of gamma distributions between the smokers and non-smokers as the 
scale parameter is approximately the same. The shape and scale parameters describe 
distribution and have an analogy to mean and variance in normal (Gaussian) 
distributions (Nonsmokers: shape = 0.91 scale = 4.89; Smokers: shape = 0.45, scale = 
4.97).  A smaller shape parameter indicates a more skewed distribution. In other words, 
there are more sites with low GCF MMP-8 levels among the smokers, but the extremely 
high MMP-8 levels can be observed in both groups; smokers and non-smokers.   
The skewed distribution of GCF MMP-8 levels at baseline may indicate implicitly 
that most sites are in steady inflammatory state of periodontitis while some sites express 
random bursts of activity. Low GCF MMP-8 levels are detected frequently in periodontitis 
sites, despite of the pocket depth or disease severity, but increasing PDs and disease 
severity associate with increasing mean levels of GCF MMP-8 and increasing statistical 
variance. In other words, higher population mean in GCF MMP-8 levels indicates a larger 
variance and the increased probability of MMP-8 “bursts”.  
Papantonopoulos et al. (2013) studied longitudinal dynamics (5-8 years follow-up 
data) in disease progression of AgP and CP patients and created a model suggesting a 
non-linear dynamic process with “features of chaos” (statistical fractal). Both AgP and CP 
patients could be modeled with a similar non-linear mathematical model, in which 
periodontitis is described to evolve through two fixed points or attractors, namely the 
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stable and unstable, but the model suggested faster progression rates for AgP patients 
compared to CP. The model was also tested with cross sectional data (Takahashi et al. 
2001), with multiple immunological parameters (from blood samples, no MMP-8 
included), similarly suggesting two partially-overlapping zones (rates) of disease activity 
(Papantonopoulos et al. 2013). 
 
5.2.  Smoking and other modifying effects on GCF MMP-8 levels 
 
The non-treated smoking periodontitis patients demonstrated lower average GCF 
MMP-8 levels compared to the non-smokers. The finding that smoking decreases oral 
fluid MMP-8 levels have also been observed in many other studies (Ding et al. 1994, 
Heikkinen et al. 2010, Ozcaka et al. 2011, Mäntylä et al. 2006). After conventional SRP 
treatment, MMP-8 levels decreased in both groups at first, but were inclined to run at the 
same levels after a few months of maintenance, except in the smokers´ group of high-
responders revealed with the cluster analysis. 
Smoking has diverse effects on periodontal tissues. There is evidence of a 
dysfunctional effect on neutrophils (Palmer et al. 2005). Decreased peripheral blood flow 
in smokers may also have an effect on the host response, GCF volume, and biomarker 
content (Morozumi et al. 2004). The low baseline GCF MMP-8 levels may denote a stable, 
quiet period in disease activity, but in smokers it may also indicate a suppressing effect 
of smoking on the host response. The increase of low baseline MMP-8 levels in the type-
2-response pattern sites can be explained as a recovery of physiological MMP-8 levels 
provoked by the treatments and a wound healing process (III and IV).  In turn, very high 
GCF MMP-8 levels may indicate the dysfunctional hyper reactivity in neutrophil response 
in the smokers´ high-responding sites. Whether the increase in GCF MMP-8 levels is 
physiological or pathological during the maintenance period depends on dynamic-
feedback mechanisms, TIMP-1 levels for example, regulating enzymatic MMP-8 activity. 
However, the statistical risk and probability for a weak or compromised treatment 
outcome can be defined for different GCF MMP-8 cutoff levels and the optimal cutoff with 
diagnostic and prognostic properties can be determined and used in point-of-care 
diagnostics.  
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The modifying effect of smoking on the GCF MMP-8 levels was one main focus of 
this thesis. However, there might be also other possible host-dependent factors that can 
cause variability in the detected GCF MMP-8 levels not analysed in this thesis. There is 
some evidence that gender might have an effect on oral fluid MMP-8 levels, for example. 
Heikkinen et al. (2010) found that there was a significant difference in salivary MMP-8 
levels between non-smoking and smoking adolescent boys and the effect was 
strengthened by the amount of smoking. However, the same effect was not found among 
same-aged girls. Actually, there was no significant difference in salivary MMP-8 levels 
between non-smoking boys and girls, but only among the smokers. The group of girls 
smoking the most (packs per year indexed) had the highest MMP-8 levels on average, but 
also the largest variance in the saliva MMP-8 levels. Notably, more females were included 
in study III relative to males. Females are also overrepresented in the groups of negative 
MMP-8 test results in the maintenance period (IV, Table 2). However, this result should 
be analysed in more detail in order to make any further conclusions. The observable 
effect can occur by chance or be a confounder and result from better compliance to oral 
hygiene instructions within the female group; this effect has been observed in many 
epidemiological studies (Haytac et al. 2013), for example. However, there might be some 
biological differences in inflammatory host responses between genders affecting also 
MMP-8 levels in oral fluid. Heikkinen et al. (2010) discussed, whether pubertal hormonal 
changes could cause differences in the salivary MMP-8 levels in the same way as was 
observed among pregnant females (Gürsoy et al. 2008, Gürsoy et al. 2010b, Gürsoy et al. 
2010a). Nevertheless, pregnancy or other major systemic conditions or diseases having 
a possible effect on host response were excluded from this study. Adolescents were not 
included in this study either.  
 The positive effect of LDD on clinical parameters compared to placebo was 
reported in the original study of Emingil et al. (2004). The effect of LDD on the GCF MMP-
8 levels was relatively small, although a significant difference was observed at 6 months 
compared to placebo. The effect of azithromycin on the clinical parameters or the GCF 
MMP-8 levels was also rather small (Emingil et al.2012, Han et al.2012). Nevertheless, 
the adjunctive medications might have had a small modifying effect on the GCF MMP- 8 
levels in study IV.  
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5.3. Comparison of MMP-8 detection methods 
 
Measuring MMP-8 levels from oral fluids is based on immunological detection 
methods, which can be divided, according to the used antibody type, into assays utilizing 
monoclonal or polyclonal antibodies. In general, monoclonal antibodies are synthesized 
within a single hybridoma cell line (hybridization of myeloma cells and B cells from an 
immunized test animal) (Winter & Milstein1991). The procedure leads to isolation of the 
hybridoma cells producing only identical antibodies detecting the same epitope on the 
antigen. In contrast, polyclonal antibodies originate from several B-cell lines and are 
capable detecting different epitopes.  Quantitative assays, like all methods in this study, 
are based on monoclonal antibodies. Conversely, in qualitative analysis (western blot for 
example), polyclonal antibodies can be a better option with a better sensitivity and 
stronger signal, but a weaker quantitative specificity. The monoclonal antibody was used 
also in the western blot analysis in this work (I) to describe the affinity of the used 
monoclonal antibody in IFMA and other POC methods. The western blot figure (I, Figure 
5) nicely demonstrates the presence of activated MMP-8 in periodontitis sites vs. the 
latent MMP-8 form in gingivitis sites.  
Detected MMP-8 levels are quite sensitive to the antibody in the assays, as was shown 
in the GCF studies I and II and also in another study with oral rinse samples (Leppilahti 
et al. 2011). Several different cell types can express MMP-8 in inflamed tissues, as 
described thoroughly in the review section. MMP-8 is secreted extracellularly in the 
latent pro-form and activated after proteolytic cleavage (Sorsa et al. 2006). Different 
MMP-8 antibodies may have different affinities against the pro-and active isoforms. In 
addition, the MMP-8 antibodies detect molecule complexes including MMP-8 (MMP-8 
bound to other molecules, heavy molecular weight complexes) or fragmented MMP-8 
molecules (I, Figure 5).  Neutrophil-originated MMP-8 is more glycosylated compared to 
de novo secreted MMP-8 isoforms (Hanemaaijer et al. 1997, Owen et al. 2004). There 
might also be diversity in the affinities of different antibodies against the glycosylated 
“physiological” neutrophil-derived MMP-8 if the used antibody is produced to detect the 
recombinant de novo MMP-8. 
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5.4. Determination of clinical treatment outcome with the cluster 
analysis 
 
The major aim in periodontal research has been to determine criteria for the active 
disease and to predict the disease progression. Probing measures, PD and CAL itself, 
indicate mainly cumulative disease history, not the disease activity at the event of 
measurement although PD give some indication regarding the current disease. BOP and 
other gingival indices, denoting visually-observed inflammation in the gingiva, have 
moderate specificity but poor sensitivity and are poor predictors of short-term changes 
(Haffajee et al. 1983). However, long-standing, chronic gingivitis can be regarded as a risk 
factor for periodontal disease progression and tooth loss (Schätzle et al. 2003, Lang et al. 
2009, Schätzle et al. 2009).  
Disease progression can be detected by measuring change in PD or CAL and bone 
loss in radiographs. However, in the classical longitudinal follow-up study with untreated 
periodontitis patients, 83% of sites lacked any significant change in probing measures 
during the 12-months follow-up (Goodson et al. 1982). From sites with significant 
change, more became shallower than deeper when the patterns of disease progression 
and regression were analyzed. Another challenge faced in a statistical analysis of 
longitudinal data is that detected significant attachment loss or pocket deepening is not 
permanent during the follow-up. Again, in the same study with untreated patients, from 
the 66 (5.7% from all sites in the study) sites with a significant increase in PD during the 
follow-up, only 22 (1.9% from all sites in the study) retained deep levels during the 
follow-up as the rest of active sites had a spontaneous remission (Goodson et al. 1982). 
Interestingly, the deeper pockets had larger variability in both directions; spontaneous 
remission and progression of the lesion (Goodson et al. 1982). The same authors noticed 
that in a longitudinal study of 6 years, only 12% expressed attachment loss of more than 
2 mm (Socransky et al. 1984). On the other hand, 40% of sites that exhibited attachment 
loss during the first three-year period, demonstrated no change in the next three years, 
and 50% of sites with no change in the first three years, had attachment loss in the last 
three years, respectively (Socransky et al. 1984). 
In our longitudinal studies, all patients received SRP treatment and some of the 
patients received adjunctive medications together with SRP. If the attachment loss is a 
relatively rare event among untreated periodontitis patients in a one-year follow-up, it is 
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reasonable to assume that it should be even more unlikely among the treated patients in 
this study, and a significantly larger sample would be needed to detect enough “true” 
progressive sites for further statistical analysis. In this study, CAL levels decreased or 
stayed unchanged in almost all sites and only few sites presented attachment loss 
compared to the baseline level. Thus, a question arises, ‘what should be the outcome 
measure in treated periodontitis patients to compare MMP-8 or other biomarkers with, 
when the disease progression is a rare phenomenon to follow in a short 6-12 months 
study period? 
 Cluster analysis of CAL change produced two distinct groups with a large and 
significant difference in the CAL change (III and IV). The difference in PD levels at baseline 
can partly explain the result, but there was a significant difference in the divergence of 
PD and CAL levels and the amount of GR between the groups. Interestingly, the “agnostic” 
cluster analysis clearly followed the dichotomy created with the traditional 2 mm cutoff 
to indicate the significant difference in the CAL change. However, the differences in the 
clinical treatment outcomes observed in this study are more likely changes in the soft 
tissue responses, in the amount of gingival recession, during the relatively short 
maintenance treatment period (6-12 months), and can be predicted, to some extent, by 
GCF MMP-8 levels as this study’s results suggested (III and IV).  The interpretation is also 
supported by the other independent MMP-8 studies (Reinhardt et al. 2010, Hernandez et 
al. 2011). If irreversible changes in the attachment levels and the detectable bone loss in 
radiographs were studied, a longitudinal study with several years of follow-up would be 
better for the detection of the true disease progression.  
 
5.5. Practical implications of GCF MMP-8 test 
 
Much research has focused on GCF biomarkers to find new adjunctive diagnostic 
tools for periodontal diseases, and  for oral fluid MMP-8 detection, the point-of-care tests 
have been developed and are under development (Prescher et al. 2007a, Munjal et al. 
2007b, Mäntylä et al. 2003, Mäntylä et al. 2006, Sorsa et al. 2015, Heikkinen et al. 2015). 
The seventh European consensus workshop distinguished five different implications 
(susceptibility, diagnostic, prognostic, predictive, and therapeutic) for biomarkers to be 
used in periodontal diagnostics described in the review section (Kinane et al. 2011). This 
 83 
 
thesis focused on three of these five implications; diagnostic, prognostic and therapeutic 
utility of GCF MMP-8 at the site level.  
Making a general diagnosis of periodontitis, detecting the periodontal attachment 
loss, and differentiating periodontitis from gingivitis or healthy sites and patients, should 
be easily done by a dental professional.  However, there are situations when dentists are 
not available and resources are too low to carry out a periodontological examination for 
the whole population in question. Thus, there is a need for a reliable but cheap and simple 
way to perform a non-invasive test for screening and diagnostic purposes (Nwhator et al. 
2014, Sorsa et al. 2015, Heikkinen et al. 2015).  
Oral fluid MMP-8 tests, employing the antibody originally described by 
Hanemaaijer et al. (1997), and later by Mäntylä et al. (2003), Leppilahti et al. (2011), 
Nwhator et al. (2014), and Heikkinen et al. (2015), have shown quite good agreement 
with the periodontal status. The first MMP-8 POC test with the antibody used in this study 
was a qualitative dip-stick test with good agreement with the IFMA analysis (kappa = 
0.81) and had the sensitivity of 0.64 and the specificity of 0.92 to differentiate 
periodontitis sites from gingivitis or healthy sites (Mäntylä et al. 2003). The portable 
quantitative POC device (dentoAnalyzer®) based on the technology developed originally 
for the detection of Streptococcus sobrinus (Munjal et al. 2007b, Munjal et al. 2007a) and 
the dip-stick test was compared with IFMA again with good correlation (r = 0.95, I). 
Nwhator et al. (2014) found that the commercially available lateral-flow (PerioMarker®) 
MMP-8 test had very high sensitivity to detect signs of chronic periodontitis (95%), poor 
oral hygiene (96%), and BOP (83%) from oral rinse samples, although the specificity of 
the test was quite low. In a very recent pilot study, initial signs of periodontitis could be 
detected with very few false positives (sensitivity 48- 76.5%; specificity 96.7-100%) in a 
population of adolescents by a commercial chair-side test (PerioSafe®) based on the 
same monoclonal antibody as in the PerioMarker®, the test-stick, or IFMA (Heikkinen et 
al. 2015). Such a test is eligible to screen people for periodontitis cost efficiently, in 
circumstances with low dental care resources (Nwhator et al. 2014, Heikkinen et al. 
2015). MMP-8 tests from GCF samples in site-level study II, and also by Mäntylä et al. 
(2003), showed a good diagnostic performance comparable to the mouth-rinse study of 
Heikkinen et al. (2015).  
 It is also pertinent to question whether there are differences in the GCF MMP-8 
levels between healthy or gingivitis sites in non-periodontitis patients and so called 
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‘shallow’ healthy or gingivitis sites (PD < 4 mm) in periodontitis patients. Few studies 
address the question. Figueredo et al. (2004) found significant decrease in the GCF MMP-
8 levels after treatment in both shallow (with gingivitis) and deep pockets of 
periodontitis patients, but periodontitis sites had higher GCF MMP-8 levels after 
treatment compared to the shallow ones. In a cross-sectional study, the same authors 
compared  GCF MMP-8 levels between gingivitis sites of non-periodontitis patients, 
gingivitis sites (shallow pockets) of periodontitis patients, and real periodontitis sites 
(with deep pockets) and found no difference in the GCF MMP-8 levels between the groups 
(Figueredo et al. 2005). Passoja et al. (2008) have an interesting aspect in their study by 
analysing the GCF MMP-8 levels in the shallow (PD < 4 mm) crevices of periodontitis 
patients. They found that GCF MMP-8 levels were typically lower in the group of shallow 
crevices compared to diseased sites (PD ≥ 4 mm). However, they found that GCF MMP-8 
levels in shallow crevices associated with the extent of attachment loss in periodontitis 
patients. All of these referred studies applied different MMP-8 detection methods, with 
different antibodies, and diverse GCF sampling methods (Figueredo et al. 2004, 2005) 
relative to the methods employed in this study and thus the results are not directly 
comparable.  Nevertheless, it was noticed earlier with IFMA method that the GCF MMP-8 
levels were at increased levels even in stable periodontitis sites after successful 
treatment compared to GCF MMP-8 levels in healthy sites (Mäntylä et al. 2006, Sorsa et 
al. 2015). In this thesis, the data inclusion criteria for a periodontitis site was PD ≥ 4 mm 
(III) and PD ≥ 5 mm (IV), and the so-called ‘shallow sites’ of periodontitis patients were 
excluded from the analysis.  
Predicting disease progression and giving a prognosis for treatment is a more 
challenging task in comparison to a simpler screening or a preliminary diagnosis of 
periodontitis.  The difficulty in finding the prognostic or predictive biomarker or a 
composition of markers in periodontitis is most likely based on the nature of the disease 
itself. The disease itself progresses in periods of exacerbations and remissions 
(Socransky et al. 1984b, Schätzle et al. 2009, Mdala et al. 2014).  An interesting finding is 
that most of the oral fluid, inflammatory host-response-reflecting biomarkers, such as 
MMP-8, -14, azurocidin, and MPO (II), obey skewed, non-normal (non- Gaussian), 
distributions and implicitly denote inflammation as a burst-like phenomenon. On the 
other hand, changes in clinical parameters seem to be more near the assumption of 
normality (Gaussian distribution). Longitudinal dynamics and a cumulative effect of 
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inflammatory bursts on the clinically-observable disease progression is a topic for 
further detailed study for better understanding.   
 Low GCF MMP-8 levels at periodontitis sites are relatively frequent, but during the 
burst of activity, MMP-8 levels (and other inflammatory biomarkers) can multiply in  an 
exponential fashion (II, III, IV). Thus, no linear nor deterministic association is evident 
between inflammatory biomarkers and the changes in clinical signs of periodontitis. The 
cutoff between physiological and pathological expression is probably not directly 
obvious in biomarker levels, but rather in the nonlinear dynamics of inflammatory 
cascades and the balance between burst and quiet periods (Papantonopoulos et al. 2013, 
Papantonopoulos et al. 2014). The detection of a single biomarker from the complex 
network of abundant interacting molecules might be considered to be a naïve approach. 
However, the cutoff between extraordinary high “signals” and frequently observed 
“noisy” fluctuations of the marker can be sorted out by exploring different longitudinal 
response patterns. It can be compared if the cutoff can differentiate also between 
pathological and physiological behavior, and further estimate the performance of the 
biomarker test, for example with likelihood ratios. A positive likelihood ratio of 1 
corresponds to “a coin flipping” as the ratio of 5 is considered a rule of thumb cutoff for 
good performance of the biological/biomarker test (Ray et al. 2010). The single GCF 
MMP-8 measurement at baseline (study IV: smokers 1.54 and non-smokers 1.88; study 
III: Smokers 3.3) could not achieve the level of 5.  Higher +LR in study III can probably be 
explained by a more homogenic population compared to the pooled data in study IV. 
MMP-8 tests during the maintenance period achieved a better prognostic utility. 
Continuously high MMP-8 levels were apparent during the maintenance period (twice as 
positive result), reaching a +LR around 5 in both the smokers´ (5.0) and non-smokers´ 
groups (4.22). If the baseline test and the maintenance test was combined, the double-
positive result (+baseline and + maintenance period) indicated +LR of 8.23 among the 
smokers and 4.12 among the non-smokers. In contrast, the double negative result yield a 
–LR of 0.55 in smokers and 0.48 in non-smokers. From this data it can concluded that the 
GCF MMP-8 test has a moderate prognostic utility on the SRP treatment and a good 
performance to monitor the treatment outcome quantitatively in both groups of smokers 
and nonsmokers when the whole 6-months follow-up from baseline to the end of 
maintenance period is considered.  
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It can be speculated that the GCF MMP-8 levels are able to reflect biological 
differences caused by smoking on inflammatory host response: neutrophil granulocyte 
functions for example. Actually, MMP-8 could give a prognosis for the site-level clinical 
treatment outcome more specifically among the smokers in studies III and IV. High-
responder results that clustered separately in study IV, support this hypothesis. 
The single “most optimal” cutoff level was chosen to study the performance of a 
simple MMP-8 test.  However, it seems that the best cutoff (estimated from the 
population) is different at baseline and during maintenance period as seen from the 
range of optimal cutoffs (for the smokers 0.015-0.065 and for the non-smokers 0.025-
0.085) conducted from the ROC analysis. Among the non-smokers at baseline, the best 
cutoff (0.085 nonsmoker) is higher compared to the maintenance period (0.025-0.045) 
as among smokers the best cutoff was at  baseline 0.055, decreased after SRP treatments 
but tended to increase again during the maintenance period (0.065 at 6 months). Among 
the non-smokers, the result is logic. Biofilm and calculus have provoked inflammation 
reflected by the increased GCF MMP-8 levels at untreated sites and by the decreased 
levels after the treatment. However, the higher “optimal” cutoff level among smoking 
patients compared to non-smokers during the maintenance period can be explained with 
the group of high-responders that was clustered as an own group (Table 7).  
Improving host-response modifying treatments is another reason that can support 
biomarker analysis in addition to focus of improving periodontal examination and the 
treatment. The effect of LDD to improve treatment outcome after conventional SRP has 
been shown in many independent studies and the Food and Drug Administration (of U.S.) 
has approved LDD as an adjunct medication to the conventional SRP for the treatment of 
chronic periodontitis (Caton & Ryan2011).  The effect of LDD is based on by its ability to 
chelate Zn2+ ion, a cofactor of MMPs, and inhibit enzymatic activity.  However, there are 
some studies where non-smokers benefit more from LDD when compared with smokers 
(Preshaw et al. 2005) and one study with smoking patients where no significant 
difference was observed in the treatment outcome between LDD and the placebo 
(Needleman et al. 2007). An interesting study hypothesis would be to study the effect of 
LDD during the maintenance period based on different MMP-8 levels at baseline. If 
sites/patients already had low MMP-8 levels at baseline, would they have a different 
treatment outcomes with the adjunctive LDD or the placebo compared to sites/patients 
with high MMP-8 levels at baseline? Although, one data from the clinical trial with LDD 
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was presented here (IV), the number of sites with LDD treatment was too small to study 
this aspect.  
 MMP-detecting antibodies/assays do not necessarily differentiate between LDD 
inhibited and active MMPs, however it is shown in many clinical studies that MMP-8 
levels decrease slightly more in LDD groups compared to the placebo (Kormi et al. 2014, 
Emingil et al. 2004, Reinhardt et al. 2010), suggesting a secondary effect of LDD on the 
MMP-8 expression. The effect was very clear in serum samples of coronary bypass 
patients who received conventional antibiotic dose of doxycycline 100 mg/day for 4 
months (LDD dose is 20 mg/day) to eradicate C.Pneumoniae to prevent secondary 
cardiovascular events (Kormi et al. 2014). 
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6. CONCLUSIONS 
 
There is significant variability between quantitative, immunological detection 
methods, based on different monoclonal antibodies, to determine GCF MMP-8 levels. 
Methods based on the same monoclonal antibody should be employed if oral fluid MMP-
8 levels are compared between independent studies.  
 Smoking has a various effect on GCF MMP-8 levels and MMP-8 response patterns 
after SRP treatment. Smokers have decreased mean GCF MMP-8 levels, which should be 
taken into account in a statistical analysis and when the diagnostic cutoff levels for MMP-
8 are defined. There is also a group of smoking patients with very high GCF MMP-8 levels, 
especially during the maintenance period, i.e. they respond to treatments with the 
exceptionally high MMP-8 levels. These high-responders have increased risk for 
compromised treatment outcomes and could potentially be targets for an adjunctive 
medication and treatments. 
Periodontitis sites can be identified diagnostically from gingivitis or healthy sites 
by utilizing GCF MMP-8 levels. GCF MMP-8 levels have also a moderate prognostic utility 
to predict site-level periodontal treatment outcome (periodontal soft tissue changes) and 
a good utility to quantitatively reflect therapeutic response on the given treatment.  
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